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a b s t r a c t
Bone is the second most commonly transplanted tissue worldwide, with over four million operations
using bone grafts or bone substitute materials annually to treat bone defects. However, signiﬁcant
limitations affect current treatment options and clinical demand for bone grafts continues to rise due to
conditions such as trauma, cancer, infection and arthritis. Developing bioactive three-dimensional (3D)
scaffolds to support bone regeneration has therefore become a key area of focus within bone tissue
engineering (BTE). A variety of materials and manufacturing methods including 3D printing have been
used to create novel alternatives to traditional bone grafts. However, individual groups of materials
including polymers, ceramics and hydrogels have been unable to fully replicate the properties of bone
when used alone. Favourable material properties can be combined and bioactivity improved when
groups of materials are used together in composite 3D scaffolds. This review will therefore consider the
ideal properties of bioactive composite 3D scaffolds and examine recent use of polymers, hydrogels,
metals, ceramics and bio-glasses in BTE. Scaffold fabrication methodology, mechanical performance,
biocompatibility, bioactivity, and potential clinical translations will be discussed.
© 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
1. Introduction
1.1. Clinical demand for bone grafts, bone substitutes & implants
The capacity for bone to self-regenerate has prompted study and
intrigue since the times of Hippocrates and Galen [1]. Despite this,
congenital and acquired pathologies including trauma, infection,
neoplasm and failed arthroplasty remain capable of leaving patients
with bone defects beyond a critical-size which the body cannot
heal. Such patients often require invasive surgical intervention to
aid healing. This can involve clinical use of bone grafts, bone sub-
stitute materials, growth factors, free ﬁbula vascularized grafts and
insertion of metalwork to aid stability and bone regeneration [2,3].
As a result, bone is the second most commonly transplanted tissue
worldwide, with at least fourmillion operationsmaking use of bone
grafts and bone substitute materials annually [4e6].
However, signiﬁcant limitations affect current treatment
options. Bone grafts taken from one part of a patient for use in their
own body (autografts) are considered the gold standard but are
restricted by the size of graft that can be harvested and carry a
further risk of donor site morbidity including infection and ongoing
pain following surgery [7,8]. Allograft tissue harvested from
cadaveric and living sources (such as femoral heads removed
during hip replacements) is in relatively greater supply compared
to autograft tissue. However, allografts carry potential risk of
disease transmission and immune response, whilst lacking a
cellular component to aid tissue regeneration. Metalwork and bone
substitutes can also be inserted to aid bone regeneration; limita-
tions associated with their use include bone thinning due to stress
shielding, wear and failure over time and risk of revision surgery
[6]. Non-invasive therapies including ultrasound treatment have
also show promise in aiding bone healing, although use is often
restricted to stable, well aligned and well reduced fracture
non-unions in adult patients [9].
To overcome the limitations of current treatment options, sig-
niﬁcant research in the ﬁeld of bone tissue engineering (BTE) has
been directed towards creating novel alternatives to traditional
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bone grafts. Porous 3D scaffolds fabricated through a variety of
methods and including a range of biomaterials have been utilised to
aid and direct bone regeneration [10e12]. However, the perfect
scaffold material has yet to be encountered and clinical translation
of 3D scaffolds has been limited as a result [13].
Bone is a heterogenous composite material with constituents
including hydroxyapatite mineral (Ca10(PO4)6(OH)2) [14], a mixed
organic component (type I collagen, lipids and non-collagenous
proteins) and water [15,16]. During scaffold manufacture it would
therefore seem logical to include a combination of materials to
create a composite scaffold, potentially allowing greater scaffold
bioactivity and structural biomimicry to be achieved.
Scaffold bioactivity is also increased by incorporating materials
that possess the ability to interact with or bind to living tissues.
Increased scaffold bioactivity can in turn lead to improved bone cell
ingrowth (osteoconduction), stable anchoring of scaffolds to host
bone tissue (osseointegration), stimulation of immature host cells
to develop into osteogenic cells (osteoinduction) and increased
vascularisation [17e20].
This review will therefore examine some of the signiﬁcant
bioactive composites that have been utilised recently in BTE after
reference to the properties of an ideal scaffold and available scaffold
manufacturing methods. 3D scaffolds that have successfully
bridged bone defects whilst actively inducing bone regeneration
will be highlighted.
2. Properties of an ideal scaffold
In general terms, the ideal 3D scaffold is composed of a
biocompatible, biodegradable material with similar mechanical
properties to the tissue which it is to be implanted in. Scaffolds by
design are not intended to be permanent implants and will ideally
facilitate host cells to deposit extracellular matrix (ECM) and
replace the scaffold structure over time. The 3D architecture of the
scaffold should be highly porous with an interconnected structure
to allow cell and nutrient migration. The scaffold surface should
also be optimised to facilitate cell attachment, proliferation and
differentiation (see Table 1). Form a surgical point of view, it is also
desirable for the scaffold material to be easily manipulated into
different shapes and sizes to allow in-situ treatment of individual
patient bone defects [13,21e23].
Scaffolds and their breakdown products must above all be
biocompatible. This requires scaffold materials to be nontoxic to
cells, easily eliminated from the body and to elicit negligible
immune response through their presence [11,24,25]. Controlled
biodegradability is also an essential characteristic for a scaffold to
achieve; if a scaffold degrades too quickly, mechanical failure could
occur. This is particularly relevant in BTE, as an implanted scaffold is
likely to undergo load-bearing and could fracture if unable to
provide mechanical support whilst new bone is forming. Similarly,
if a scaffold does not degrade sufﬁciently quickly an inﬂammatory
response could be triggered towards the foreign material of the
scaffold, impairing tissue regeneration [26].
Growth factors also have a signiﬁcant role to play in successful
bone tissue engineering scaffolds. The processes of new bone for-
mation and extracellular matrix deposition are regulated by a range
of growth factors and biomolecules. Bone morphogenic proteins
(BMP) play a critical role in bone and cartilage development, and
have the ability to trigger proliferation and differentiation of
osteoprogenitor cells [27]. There are several examples of scaffolds
that have successfully incorporated BMPs resulting in improved
bone formation. However, risk of bone formation within soft
tissues, or heterotopic ossiﬁcation, is also associated with use of
BMPs [28e32]. Vascular endothelial growth factor (VEGF) has also
frequently been included in scaffolds, with desirable properties
including the ability to enhance blood vessel formation and bone
formation in vivo [33e35]. Transforming growth factor b (TGF b),
platelet-derived growth factor (PDGF), insulin-like growth-factor 1
(IGF-1), and ﬁbroblast growth factors (FGFs) provide further ex-
amples of growth factors that have been utilised in bone and
cartilage tissue engineering [36,37].
The microarchitecture of scaffolds is also centrally important in
encouraging cell viability and fostering tissue ingrowth. An inter-
connected pore structure, in the absence of an engineered blood
supply, allows inwards diffusion of oxygen and nutrients and
outwards diffusion of waste products from the scaffold. Porosity
also supports cell migration into the scaffold and improves avail-
able surface area for cell-scaffold binding and interaction with
surrounding tissues [38e40] (Fig. 1A and B). Individual pore size
within the scaffold is also an important consideration. It has
previously been shown that scaffold pore density and size signiﬁ-
cantly impact upon cellular growth and attachment [41,42]. As pore
size decreases, the surface area of the scaffold increases. This in-
creases the availability of scaffold ligands for cells to bind to and
interact with. However, if pore sizes become too small, cells may
struggle to migrate into the scaffold structure. Scaffolds must
therefore be precisely engineered with parameters favourable to
the cells and tissue that they will be exposed to. For example, it has
Table 1
Summary of desirable scaffold properties.
Scaffold
Characteristics
Desirable Features
Biocompatibility  Non-toxic breakdown products
 Non-inﬂammatory scaffold components, avoiding immune rejection
Biodegradability  Controlled scaffold degradation which can complement tissue ingrowth whilst maintaining sufﬁcient support
 Degradable by host enzymatic or biological processes
 Allows invading host cells to produce their own extracellular matrix
Bioactivity  Scaffold materials that can interact with and bind to host tissue
 Osteoconductive and osteoinductive properties
 Inclusion of biological cues and growth factors to stimulate cell ingrowth, attachment and differentiation
Scaffold Architecture  Interconnected pores allowing diffusion and cell migration
 Microporosity to present a large surface area for cell-scaffold interactions
 Macroporosity to allow cell migration and invasion of vasculature
 Pore size tailored to target tissue and cells
 Sufﬁcient porosity to facilitate cell ingrowth without weakening mechanical properties
 Inbuilt vascular channels to enhance angiogenesis in vivo
Mechanical
Properties
 Compressive, elastic and fatigue strength comparable to host tissue allowing cell mechanoregulation to occur and structural integrity to remain
in vivo
 Scaffold material that can be readily manipulated in the clinical environment to treat individual patient bone defects
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been shown that scaffolds implanted in vivowith pore sizes close to
300 mm promote osteogenesis due to higher permeability and po-
tential for vascularisation, whereas smaller pore sizes closer to
100 mm are more favourable for chondrogenesis [43e45]. Increased
scaffold macroporosity has also been shown to improve angio-
genesis in vivo [46], whilst a degree of microporosity (pores with
diameters lower than 10 mm) can improve cell-scaffold interactions,
resulting in osteogenic effects [47e49]. Scaffolds for BTE therefore
need to contain a mixture of macropores allowing cell and osteon
ingrowth in vivo, and micropores to encourage cell-scaffold ligand
interactions [50].
In addition to pore size and overall porosity, mechanoregulatory
effects are thought to be key in inﬂuencing bone tissue growth and
cellular differentiation in vivo. If a scaffold is unable to replicate the
mechanical forces transferred to cells in physiological conditions,
cells may be stimulated to differentiate away from an osteogenic
lineage towards an undesirable morphology [52e54]. Selecting
scaffold materials with similar stiffness to native bone would
therefore seem advantageous [55,56]. However, scaffold mechani-
cal stiffness and porosity are directly conﬂicting physical proper-
ties, with mechanical strength inversely related to increasing
scaffold porosity. In terms of load bearing, important scaffold me-
chanical properties include Young's modulus (also known as elastic
modulus, a measure of the stiffness of a solid material), compres-
sive strength (capacity of a scaffold to withstand loads tending to
reduce size) and fatigue strength (the highest stress that a material
can withstand for a given number of cycles without breaking)
[11,57,58]. The ideal scaffold would have a compressive strength
comparable to cortical bone, which along the long axis is approx-
imately 100e230 MPa, with a Young's modulus close to 7e30 GPa
and a tensile strength of 50e151 MPa [59e62]. Ideally this
compressive strength would be complemented by a porosity be-
tween 60% and 90% and an average pore size of >150 mm [63,64].
Achieving a successful balance in vivo between the properties of
a scaffold favourable to cellular function, cellular viability and
mechanical integrity under load bearing therefore remains chal-
lenging [65,66].
3. Scaffold fabrication methods
A large variety of techniques have been used in the fabrication of
3D scaffolds, sometimes in combination. In general, it is difﬁcult to
create complex scaffold microarchitectures with precise control
using conventional techniques. However, the integration into BTE
of 3D printing using computer-aided design (CAD) modelling has
greatly increased scaffold manufacture precision and repeatability,
with control over scaffold macro- and microporosity possible. The
advantages and disadvantages of conventional scaffold
manufacturing methods and more recent 3D printing techniques
will therefore be discussed and summarized in this section (see
Table 2).
3.1. Conventional scaffold fabrication
Solvent casting/particulate leaching is a traditional method of
scaffold manufacture that begins with dissolution of a polymer in
an organic solvent (Fig. 2A). The technique uses porogens, sub-
stances that can be dispersed into a moulded structure and sub-
sequently dissolved once the structure has set, resulting in the
creation of pores. Porogens are added to the polymer solution to
create a polymer-porogen network. The polymer is subsequently
hardened as the solvent evaporates, with water then used to
dissolve the porogen which is often a salt such as sodium chloride.
A hardened polymer scaffold with a porous network is left behind,
although it is difﬁcult to control pore shape and pore inter-
connectivity of scaffolds produced by this method [67,68].
Gas foaming eliminates the use of solvents deployed in solvent
casting/particulate leaching methods (Fig. 2B). This technique cre-
ates a porous structure through the nucleation and growth of gas
bubbles dispersed throughout a polymer. Compression moulding is
ﬁrst used to create solid discs of a scaffold material, such as pol-
y(lactic-co-glycolic acid), within a heatedmould. Following this, the
discs are saturated with carbon dioxide by exposure to high pres-
sure CO2 gas (5.5 MPa) for 72 h at room temperature, before solu-
bility of the gas in the polymer is rapidly decreased by reducing CO2
pressure to atmospheric levels (P0CO2). This causes the CO2 gas to
clump together, creating pores. Porosities of up to 93% and pore
sizes of up to 100 mm can be obtained using this technique.
However, it is difﬁcult to control pore connectivity and pore sizes by
gas foaming [7,68e70].
Freeze-drying begins with freezing of a polymer solution,
resulting in the formation of solvent ice crystals surrounded by
polymer aggregates (Fig. 2C). The surrounding pressure is then
reduced via a vacuum, to a level lower than the equilibrium vapor
pressure of the frozen solvent (P0). The solvent is thus triggered to
undergo sublimation directly into gas from the solid phase. When
the solvent is completely sublimated, a dry polymer scaffold with
an interconnected porous structure remains. Emulsiﬁcation freeze
drying can also be used as a primary scaffold fabrication method.
The process begins by dissolving polymers/ceramics in a solvent
Fig. 1. (A) SEM image showing interconnected porous structure of human trabecular bone (B) Pores and interconnecting pores demonstrated in hydroxyapatite scaffold. Pores are
circled; arrows indicate interconnecting pores which allow communication between pores. Adapted from Doi et al. [51].
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and then mixing with water, to obtain an emulsion. The mixture is
poured into amould and frozen before the two phases can separate.
The frozen emulsion is then freeze-dried to remove the solvent and
dispersed water, creating pores in a solidiﬁed scaffold [72].
Phase separation relies on changes in thermal energy to induce
the de-mixing of a homogenous polymer/solvent solution. When a
polymer such as PLLA is dissolved in a solvent, it can become
thermodynamically unstable at a low temperature and spontane-
ously separate into a polymer-rich phase and a solvent-rich phase.
Phase separation scaffold manufacture takes advantage of this
phenomenon and begins with dissolution of a polymer in a high-
boiling, low molecular weight solvent at an elevated temperature,
typically around the melting point of the polymer, allowing for-
mation of a homogenous melt-blend. The solution is then cast into
a desired scaffold shape, and cooled in a controlled manner to
induce phase separation and precipitation of the solution into a
polymer-rich phase and a solvent-rich phase, creating a nano-
ﬁbrous matrix (Fig. 2D). The solvent which is in the solvent-rich
phase will then be removed through extraction, evaporation, or
sublimation. This creates a porous scaffold, as removal of the sol-
vent leaves pores behind in the polymer matrix.
Electrospinning is another popular scaffold fabrication tech-
nique with the ability to create nanoﬁbrous interconnected porous
scaffolds (Fig. 2E). This method uses an externally applied electric
ﬁeld to draw charged threads of polymer solutions or polymer
melts as thin jets from a capillary tube towards a collector plate.
Fibres in the micro- and nanometre range can be created and
deposited sequentially to create a scaffold, with potential to include
composite materials and biomolecules [73e76].
3.2. 3D printing techniques
The traditional methods of scaffold fabrication that have been
discussed in brief so far generally offer limited control over pore
size, geometry and interconnectivity. Overtime there has been an
improvement in the ability to spatially control scaffold micro-
architecture and spatial content as technologies such as 3D printing
have emerged. In general, 3D printing fabricates objects via layer-
by-layer processing of powder, liquid or solid material substrates.
Starting from the bottom and building up, each newly formed layer
is triggered to adhere to the previous layer, resulting in the creation
of construct of gradually increasing size. The structure of a 3D
printed object is dictated by a computer-aided design (CAD) model
loaded onto a 3D printer. CADmodels describe 3D objects in a series
of cross-sectional layers, allowing 3D printers to physically repro-
duce models through an additive process.
Patient speciﬁc CAD models can be created by converting
computed tomography (CT) or magnetic resonance imaging (MRI)
of clinical defects into (CAD) models. Further software is then used
to slice CAD models into G-code, which encodes 3D CAD models in
a format that can control 3D printers. Parameters such as print
speed, layer height, print head temperature and pressure can all be
modiﬁed and optimised through G-code.
Several 3D printing methods have been adapted into BTE, with
stereolithography (SLA) representing one of the earliest 3D printing
techniques to have been developed (Fig. 3A).
It relies on the directed use of a laser to polymerize liquid UV-
curable photopolymer resin layer-by-layer, resulting in a solidi-
ﬁed 3D model. The UV laser can solidify the model's cross-section,
Table 2
Comparison of scaffold fabrication methods.
Manufacturing
Method
Beneﬁts Potential Limitations
Solvent casting/
particulate
leaching
 Relatively simple technique that allows creation of scaffolds with regular porosity,
controlled composition and pore size.
 Use of organic solvents precludes cells and
biomolecules being included directly in
scaffolds
 Can be difﬁcult to control pore shape and
interconnectivity
 Limited thickness of structures and
mechanical properties achievable
Gas Foaming  Eliminates use of chemical solvents  High pressures involved prohibits inclusion
of cells and bioactive molecules directly
into scaffolds
 Temperature labile materials may be
denatured during compression moulding
step
 Difﬁcult to control pore sizes and ensure
interconnectivity
Emulsiﬁcation
Freeze-Drying
 Does not require use of solid porogen  Requires use of organic solvents
 Small pore size and
 Porosity often irregular
 Long processing time
Phase Separation  Eliminates leaching step of porogen
 Can be combined with other techniques easily
 Small pore sizes limit use
 Use of organic solvents inhibits use of
bioactive molecules or cells during scaffold
fabrication
Electrospinning  Creates scaffold with large surface area for cell attachment
 Simple and inexpensive technique
 Organic solvents may be required, which
can be harmful to cells
 Limited mechanical properties
 Difﬁcult to incorporate precise
microarchitecture into constructs
3D Printing
 SLA
 SLS
 FDM
 Inkjet
 Laser-assisted
 Microvalve
 Microextrusion
 Complex 3D shapes with high resolution, controlled pore size & morphology and controlled
internal structures can be fabricated. Improved capacity to incorporate vascular structures
into constructs
 Depending on technique used, cells may be included in high concentration directly in
scaffold materials
 Some techniques are limited by printable
materials
 Set up costs can be expensive for machinery
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Fig. 2. Common scaffold fabrication techniques. (A) Solvent casting-particle leaching process (B) Gas foaming (C) Freeze-drying (D) Phase separation (E) Electrospinning. Adapted
from Puppi et al. [71].
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leaving remaining areas in liquid form. After each cross-section, the
print platform moves down, covering the solid polymer with
another layer of resin for curing. Excess resin that has not been
cured is then removed from the 3D structure, allowing rapid
fabrication of a structure that can be cured further in an oven.
Whilst SLA can quickly produce scaffolds with controlled archi-
tecture and micrometre-level resolution, there is a limited number
of materials applicable to this costly technique [78].
Fused deposition modelling (FDM) uses a temperature
controlled printhead to deposit thermoplastic material onto a
platform in a layer by layer manner to build up a 3D construct
(Fig. 3B). A thermoplastic ﬁlament is driven into a heated printhead,
causing the ﬁlament to melt, allowing thin layers of a semi-molten
polymer such as polycaprolactone to be precisely deposited
sequentially. The molten ﬁlament cools in the air of the print
environment, allowing ﬁlaments to fuse together rapidly to create a
scaffold. FDM has been successfully adapted into BTE as method of
producing synthetic scaffolds, although the elevated temperatures
involved limit the inclusion of biomolecules and hydrogels [79,80].
Selective laser sintering (SLS) involves the use of a computer
controlled laser beam to fuse layer-upon-layer of a powder, sin-
tering the powder material together to build a solid 3D structure
(Fig. 3C). Some success with this technique has been demonstrated,
through the production of bioactive, composite scaffolds with
similar mechanical properties to trabecular bone [81,82]. However,
the elevated temperatures involved in the process limit the inclu-
sion of cells and biomaterials directly into SLS scaffolds.
3.3. 3D bioprinting
As an emerging technology, 3D bioprinting offers a potential
solution to help ease the burden of arthritis and other cause of bone
defects within orthopaedics. Bioprinting can be used to deposit
living cells, extracellular matrices and other biomaterials in user-
deﬁned patterns to build complex tissue constructs “from the
bottom up.” The potential to create inherent vascular structures is
also improved by bioprinting, as internal channels containing
vascular cells can be printed into constructs, fostering the ingrowth
of blood vessels in vivo. By contrast, the conventional tissue engi-
neering method of seeding cells onto a pre-fabricated scaffold does
not allow for precise 3D placement of cells or biological content,
limiting capacity to create complex hierarchical tissue constructs
[83,84].
The process of bioprinting typically begins with the selection of
cells and biomaterials for inclusion in bioprinted constructs (Fig. 4).
Cells for printing can be sourced from tissue biopsies, blood sam-
ples and from other sources, and expanded in number through
culture to maximise cell density on bioprinting. The additional step
of 3D cell culture may also be performed to creating aggregates of
cells for printing. Cell aggregates or spheroids have superior
intercellular communication and extracellular matrix development
when compared to cells grown in 2D culture, potentially acceler-
ating the growth of printed constructs towards functional tissue
after bioprinting [85]. Mesenchymal stem cell spheroids also
exhibit enhanced in vitro and in vivo osteoregenerative potential
compared to MSCs cultured in monolayer [86,87].
Fig. 3. Common 3D Printing Techniques. (A) Stereolithography (B) Fused deposition modelling (C) Selective laser sintering. Adapted from Jaster L [77].
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Following culture, cells and selected biomaterials such as hy-
droxyapatite are encapsulated in a delivery medium, or bioink.
Print cartridges containing bioink are then loaded into a 3D bio-
printer, which dispenses the bioink in a pre-determined 3D ge-
ometry according to a CAD model. Bioprinters often have multiple
print nozzles, allowing combinations of cells and biomaterials to be
includedwithin a printed construct. A high degree of spatial control
can therefore be achieved over construct architecture and content
[88,89]. Following printing the construct can be directly implanted
into a patient, or alternatively matured ﬁrst in vitro. Biologically
active culture environments known as bioreactors are available to
help direct and support cell growth towards speciﬁc tissue types.
3.4. 3D bioprinting techniques
Commonly used bioprinting techniques include inkjet, laser-
assisted, microvalve and extrusion bioprinting.
Inkjet bioprinting (or drop-on-demand bioprinting) uses ther-
mal or acoustic forces to eject droplets from a pint head nozzle
(Fig. 5A). Thermal inkjet printers use heat to generate a pressure
pulse within a print head for a brief period, causing ejection of a
droplet of bioink. Other systems rely on piezoelectric crystals,
which becomemechanically stressed by the application of a voltage
and as a result change shape. This generates an acoustic wave
which in turn creates sufﬁcient pressure to eject droplets from a
nozzle. As a technology adapted form desktop inkjet printers,
beneﬁts include low cost, wide availability and high print speed.
However, limitations include frequent nozzle clogging, risk of
exposing cells and materials to thermal and mechanical stress and
nonuniform droplet size. The liquid droplet deposited is also of low
viscosity, relying on further gelation or crosslinking to create a solid
structure [90e92].
Laser-assisted bioprinting (LAB) systems avoid the use of a
nozzle; instead they rely on a pulsed laser beam to generate a high-
pressure bubble, which in turn propels cell-containing materials
toward a collector substrate from an initial print material “ribbon”
(Fig. 5B). Recently Keriquel et al. used LAB to print mesenchymal
stromal cells, associated with collagen and nano-hydroxyapatite,
directly in situ onto a mouse cranial defect to aid bone regenera-
tion [93]. Some limitations of LAB include potential heat-induced
damage to cells, difﬁculty of creating 3D structures, high system
costs and the time-consuming nature of creating ribbons with high
cell and biomaterial concentrations [94].
Microvalve bioprinting is a droplet-based system where ﬂuids
under a constant pneumatic pressure are dispensed from cartridge
tips by opening and closing a small valve (Fig. 5C). The valve in
question can be controlled mechanically, electrically or magneti-
cally. Microvalve systems can print cells including MSCs with high
viability and functionality, with deposition of other biomaterials
also possible such as collagen and bone morphogenic protein
[95e97].
Extrusion bioprinters deposit continuous ﬁlaments of materials
rather than individual droplets (Fig. 5D). Pneumatic or mechanical
pressure is applied to a syringe to cause bioink extrusion through a
nozzle. A signiﬁcant advantage of this approach is the ability to
deposit very high cell densities, with some studies manging to
Fig. 4. Summary of bioprinting process.
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purely print cells, for example as ﬁlaments of cartilage [98]. A broad
range of bioinks have been successfully extrusion bioprintined,
including tissue spheroids, tissue strands, cell pellets, decellular-
ized matrix components and cell-laden hydrogels. Potential limi-
tations and challenges include achieving high print resolution,
shear stress effect on cells within print nozzles and development of
printable bioinks [99].
4. Materials used within bone tissue engineering
Materials that have been utilised within bone repair and
regeneration include metals, ceramics, polymers, hydrogels and
related composites. Groups of materials will be reviewed in the
following corresponding sections and summarized (see Table 3).
4.1. Metals
Metal alloys such as cobalt-chromium, zirconium, titanium and
stainless steel have excellent biocompatibility and strength
[21,100]. As such, they are commonly used in joint replacement and
fracture ﬁxation implants to offer support for healing bone [101].
However, a lack of biodegradability makes them less suited to BTE
where the aim is for native tissue to resorb and replace implanted
constructs. Additional surgery is often required to remove metallic
implants, particularly when they are used in paediatric patients
who have not reached skeletal maturity [102]. The superior elastic
modulus of metals relative to bone can also predispose to stress
shielding occurring. In this phenomena, mechanical bypass of loads
occurs in the bone surrounding implants, leading to bone resorp-
tion and increased fracture risk [103]. Despite these limitations,
some success has been achieved through creation of composite
metal scaffolds. Strontium (Sr) was combined via freeze-drying
with hydroxyapatite (HA) and chitosan (CS) by Lei et al. to create
composite nanohybrid scaffolds. The presence of SrHA nanocrystals
in the scaffolds was found to signiﬁcantly enhance cell proliferation
and osteogenic differentiation of human bone marrow mesen-
chymal stem cells (hBMSCs) [104]. Hierarchical structure was
developed by Wu et al. on a microporous nickel-titanium com-
posite (NiTi) scaffold by treating the surfacewith sodium hydroxide
in a hydrothermal reaction. This led to the creation of a nano-
structured, microporous exposed surface on an already micropo-
rous NiTi scaffold. Improved surface hydrophilicity, deposition of
Fig. 5. Common bioprinting techniques: (A) Inkjet, (B) Laser-assisted, (C) Microvalve, and (D) Extrusion bioprinting.
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hydroxyapatite, accelerated cell attachment and proliferation was
seen in vitro as a result [105]. Titanium based scaffolds were also
fabricated by Chen et al., who sintered microporous Ti spheres and
Ti powder. Maximum porosity of 50% was achieved, with scaffold
compressive strength reported to be up to 109 MPa. In vitro, the
microporosity of the scaffolds helped promote attachment and
growth of mesenchymal stem cells (MSCs) [106].
Chou et al. utilised 3D inkjet printing to create iron-magnesium
(FeMg) composite scaffolds (Fig. 6). Following 3D printing, the
FeMg constructs were found to have an open, porous structure with
similar tensile mechanical properties to cancellous bone. In vitro
analysis found good cell viability on exposure to the scaffolds, with
cell inﬁltration into pores also seen [107].
Selective laser sintering (SLS) is another 3D printing method
that has used to successfully produce composite metallic scaffolds.
Layer-upon-layer of a titanium powder and silica sol slurry were
sintered by Liu et al. to produce composite titanium-silica scaffolds
with complex geometry [108]. Scaffold compressive strength was
increased by heat treatment post-fabrication, with signiﬁcant hu-
man sarcoma cell (MG63) proliferation seen over 7 days. However,
the signiﬁcant heat involved in manufacturing metallic scaffolds
using SLS and other methods limits the potential to directly include
biomolecules. Attempts have therefore been made to coat the
surface of metallic scaffolds with bioactive ceramics such as HA and
calcium silicate [75].
Stainless steel, titanium and cobalt chromium alloys have all
been combined using SLS and secondarily modiﬁed using phos-
phonic acid. This process results in the creation of a composite
scaffold with a biocompatible phosphonic layer on the scaffold
surface. Biomolecules and drugs including paracetamol and anti-
biotics have then been successfully deposited on scaffold phos-
phonic acid surfaces, improving bioactivity [109,110].
Table 3
Comparison of scaffold materials.
Manufacturing
Material
Beneﬁts Potential Limitations
Hydrogels  High water content/growth media inclusion allows for cell encapsulation
and growth
 Mechanical properties can be modiﬁed through crosslinking
 Controlled drug/growth factor release possible
 Ease of patterning via 3D printing to mimic tissue microarchitectures
 Mechanical properties limit use in load bearing constructs
 Optimising printing conditions for individual hydrogels can be time
consuming
 Physical manipulation of constructs can be difﬁcult
 Loading evenly with cells can be challenging
Polymers  Natural polymers can be derived from extracellular matrix, ensuring
high biocompatibility and low toxicity
 Biodegradable
 Often contain biofunctional molecules on their surface
 Synthetic polymers offer improved control over physical properties
 Natural and synthetic polymers generally lack mechanical properties
for load bearing
 Pathological impurities such as endotoxin may be present in natural
polymers
 Synthetic polymers are often hydrophobic and lack cell recognition
sites
Ceramics  Osteoconductive and osteoinductive properties allow strong integration
with host tissue
 Similar composition to host bone mineral content
 Can be delivered as granules, paste or in an injectable format
 Hard and brittle when used alone
 May display inappropriate degradation/resorption rates, with decline
in mechanical properties as a result
Bioactive glasses  Osteoconductive, osteoinductive properties
 Adapted into clinical prosthesis already
 Inherent brittleness
 Difﬁcult to tune resorption rate
 Manipulation of constructs into 3D shapes to treat speciﬁc defects
challenging
 Potential for release of toxic metal ions
Metals  Biocompatible
 Superior strength
 Superior mechanical properties can be advantageous in situations where
slow bone growth likely
 Superior modulus can lead to stress-shielding
 Poor biodegradability may result in further surgery/impairment of
tissue ingrowth
 Secondary release of metal ions may cause local and distal toxicity
Fig. 6. SEM images of MC3T3 cells on the surface of 3D-printed FeeMg scaffold. White arrow denotes a cellecell junction after one day; black arrows denote cellular extensions to
pore walls after 3 days [107].
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4.2. Bioceramics
Bioceramics, including ceramic composites, amorphous glasses
and crystalline ceramics, show great promise within BTE as me-
chanically strong materials, with favourable bioactivity [111].
Further material properties can include corrosion resistance,
resistance to compression, and a weakness to shearing and tensile
forces, resulting in brittleness [112].
Perhaps the most frequently utilised crystalline bioceramics in
BTE are calcium phosphates (CaPs), partly due to their prevalence in
native bone tissue [113]. Hydroxyapatite (HA), tricalcium phos-
phate (TCP) and a composite of both substances known as biphasic
calcium phosphate (BCP) have all been adapted in BTE scaffolds.
Cell mediated degradation of these ceramics in vivo produces cal-
cium and phosphate ions, which promote new bone formation
through osteoinduction [114,115]. CaPs also share a large degree of
similarity in structure and chemical composition to the mineral
content of native bone. This allows CaP constructs to provide a
biocompatible, osteoconductive interface capable of facilitating
integration with host tissue without formation of scar tissue
[116,117].
HA has excellent properties for BTE, including biocompatibility,
controlled degradation and lack of cytotoxicity. HA also has a strong
compositional similarity to bone, with proven osteoinductive and
osteoconductive properties allowing HA constructs to form a strong
bond with surrounding bone [118,119]. HA can also stimulate
endogenous expression of osteogenic growth factors such as bone
morphogenetic protein (BMP) and enhance alkaline phosphatase
(ALP) activity in mesenchymal stem cells (MSCs). This is
particularly important as ALP activity is pivotal in the early
mineralization process associated with bone formation [120e122].
However, in common with other ceramics, HA has properties of
being hard and brittle, which limits HA construct load-bearing and
manipulation into shapes speciﬁc to individual bone defects. HA
also has a slow degradation rate in vivo which can predispose to
mechanical failure at implant sites [114,119]. To overcome these
mechanical limitations, HA has been combined with several natu-
rally occurring and synthetic polymers to create composite scaf-
folds, as will be discussed later [17,30,123e129].
Dicalcium phosphate (DCP) has been used much less frequently
than HAwithin BTE, due to weak, brittle mechanical properties and
a high in vivo resorption rate [115]. Although DCP/synthetic poly-
mer composites have been produced resulting in improved me-
chanical properties, success has been limited in comparison to HA
and tricalcium phosphate based scaffolds with degradation rates
difﬁcult to control [130e132].
Tricalcium phosphate (TCP) is another popular bioceramic that
has been adapted into BTE, with commercial products already
available. Beta-TCP (b-TCP) beads have been combined with algi-
nate gels to create injectable 3D scaffolds, capable of supporting
in vivo osteogenic differentiation of MSCs [133] (Fig. 7). The b-TCP
allotrope has also been combined with type I collagen to produce
porous scaffolds with equivalent clinical performance to autografts
in a spinal fusion model [134]. Nanocomposite TCP/collagen scaf-
fold performance has also been compared favourably to HA scaf-
folds in vivo. Histologically advanced bone formation was found
after 45 days in TCP/collagen scaffolds that had been implanted in a
rabbit segmental femur bone defect, with superior results found
Fig. 7. Photograph of injectable 3D-formed composite of b-TCP beads and alginate capable of triggering MSC osteogenic differentiation in vivo. (A) and light microscope photograph
of the composite (B). SEM photographs of the composite (C) and surface of the composite (D). The composite was composed of b-TCP beads (*) and alginate (#). Adapted from
Matsuno et al. [133].
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compared to implanted HA scaffolds [135].
Tarafder and Bose 3D printed a TCP scaffold, with poly-
caprolactone (PCL) and alendronic acid coating (AL) of the scaffold
performed post-fabrication [136]. It was found that in vivo local AL
delivery from PCL-coated TCP scaffolds led to increased early bone
formation compared to bare TCP and PCL coated TCP scaffolds.
A further study 3D printed a composite 3D TCP scaffold, with
magnesium oxide and silicon dioxide doping incorporated into the
scaffold design [137]. Signiﬁcantly higher bone and blood vessel
formation was seen in Mg and Si containing scaffolds compared to
bare TCP controls in vivo. However, the hard material based scaffold
lacked a soft niche to support neo-angiogenesis in vivo. This ulti-
mately impaired integration of the construct into host rat tissue.
Overall the results suggest that magnesium and silicon incorpo-
rated into 3DP TCP scaffolds could have potential for future bone
tissue repair and regeneration.
Rakovsky et al. employed salt leaching to create a composite b-
TCP and polylactic acid (PLA) scaffold. Composite scaffolds were
produced with 50% porosity and a large pore size (300e420 mm),
potentially favourable to BTE. Further analysis found a compressive
strength of ~5MPa, comparable to trabecular bone, although in vivo
cellular response was not assessed [138].
Silica-based bioceramic composites have also received signiﬁ-
cant attention within BTE. The ionic breakdown products of Si-
containing scaffolds have the attractive property of being osteo-
conductive [75,139e142]. Feng et al. created a calcium silicate
matrix via SLS as a starting point and incorporated HA whiskers to
improve scaffold strength. It was found that compressive strength
of scaffolds with ~45% porosity increased from 15 MPa to 27 MPa
with the addition of 20 wt% HA whiskers. Furthermore, scaffold
degradation rate decreased as HA whisker content increased.
Mineralization of apatite occurred on the scaffold surfaces in vitro,
with osteoblast-like MG-63 cells seen to inﬁltrate the scaffolds and
proliferate with increasing culture time [143] (Fig. 8).
Dai et al. sintered CaCO3 and SiO2 to create a novel, porous b-
dicalcium silicate (b-Ca2SiO4) scaffold. Mechanical analysis found
maximum scaffold compressive strength of 28.1 MPa and porosity
of up to 71%. Good biocompatibility was also evident, with MG-
63 cells andMSCs proliferating on the scaffolds in vitro, with surface
apatite formation also seen. In vivo analysis in mice found bone
tissue generation in the scaffolds after 9 weeks, suggesting
osteoinductive scaffold properties [144].
Feng et al. utilised 3D printing in the form of SLS to fabricate
composite akermanite (Ca2MgSi2O7) scaffolds reinforced with
nano-titania particles. They reported a maximum compressive
strength of 23MPa for scaffolds with ~58% porosity after addition of
5 wt% nano-titania. Fracture toughness, hardness, compressive
strength and stiffness were signiﬁcantly increased with increasing
nano-TiO2 content from 0 to 5 wt%. Bone-like apatite was formed
on the scaffolds in vitro, with MG-63 cells adhering to the scaffolds
and proliferating well [145].
Properties such as corrosion resistance, biocompatibility and
stiffness have led to widespread use of bioceramics within clinical
orthopaedics. Thousands of patients already beneﬁt from ceramic
joint replacement components, and ceramic powders and granules
used for ﬁlling bone defects [146,147]. However, within the context
of BTE, ceramic scaffolds can be prone to brittleness. In common
with metallic based scaffolds, they also have degradation rates that
can be difﬁcult to ﬁnely control. Increasing attention has therefore
been applied to developing ceramic/polymer composite scaffolds,
which will also subsequently be reviewed.
4.3. Bioactive glasses
Bioactive glasses (BGs) represent a subgroup of ceramic mate-
rials that have been extensively researched within the ﬁeld of BTE.
BGs can be considered as surface reactive glass-ceramic bio-
materials with amorphous structures. This group of materials was
ﬁrst pioneered by Professor Larry Hench at the University of Florida
in the late 1960s, as he sought to ﬁnd a bone substitute materials to
treat Vietnam War veterans [148]. The ﬁeld of BGs began with
development of Na2OeCaOeSiO2eP2O5 glasses, the most bioac-
tive of which is known as 45S5 Bioglass®. Once implanted, BG
dissolution helps create a biologically active layer of HA on the
surface of the glass, which in turn interacts with the collagen ﬁbrils
in host bone to create a strong bond. In fact, the bond formed with
bone is so strong that BG often cannot be removed with breaking
the surrounding bone [149]. Dissolution products such as calcium
and silica ions are also thought to stimulate host cells to produce
bone matrix [18,150]. Within bone, BGs can act as osteoconductive
materials, although evidence for osteoinductive properties is more
limited [151,152]. The interconnected porous structure of BGs is
similar to trabecular bone, providing cells with a temporary tem-
plate to regenerate into [153].
The two main manufacturing processes used to make glass are
melt-quenching and the sol-gel route. Melt-quenching involves
melting oxides together at elevated temperature, before quenching
them together in water or a graphite mould; 45S5 BG and other
commercial bioactive glasses are made by this method. Compo-
nents of different size and shape can be produced through this
method, including prosthetic middle ear ossicles [154].
Clinical applications of BGs have so far included prostheses used
in the ﬁelds of orthopaedic and maxillofacial surgery; granules and
particulates have also been used in place of conventional bone
Fig. 8. SEM images of (A) 10% and (B) 30% HA whiskers present in calcium silicate matrix. Adapted from Feng et al. [143].
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grafting to aid treatment of chronic osteomyelitis, soft tissue de-
fects and wounds [18,155,156]. More than a million patients within
orthopaedics and maxillofacial surgery have now had bone defects
repaired with 45S5 Bioglass® [148]. Within the ﬁeld of spinal sur-
gery, a study comparing 45S5 Bioglass® versus iliac crest autograft
for spinal fusion in adolescent idiopathic scoliosis (AIS) demon-
strated positive results in a series of 88 patients. 45S5 BG® was
found to be as effective as iliac crest graft, the current gold standard
for spinal fusion, in terms of ability to achieve deformity correction
and spinal fusion in AIS patients. Additionally, the morbidity of
harvesting an iliac crest graft was avoided in BG patients, who also
experienced fewer complications [157].
Whilst properties such as bioactivity and osteoconductivity are
attractive, the inherent brittle nature of bioactive glasses represents
a major potential limitation in their clinical application [155,158].
Through incorporation of biodegradable polymers to create BG
composites, properties such as porosity, degradation rate and
elastic modulus can be improved [159,160].
Vergnol et al. investigated the potential of a polylactic acid
(PLLA)-bioactive glass composite for bone ﬁxation devices. PLLA
has previously been reported to require up to 4 years to fully
degrade in humans and lacks osteointegration ability [161]. The
in vivo behaviour of PLLA-HA composites has already been inves-
tigated, with osteointegration found to be signiﬁcantly improved in
PLLA-HA composites compared to pure PLLA structures [162e165].
Vergnol et al. therefore attempted to characterise the performance
of 45S5 BG® -PLLA composites in vitro and in vivo. Composites
containing increasing 45S5 BG® content with PLLA were manu-
factured by injection moulding and tested for up to 56 days in
simulated body ﬂuid (SBF). Whilst formation of a mineralised or HA
layer was not seen on the surface of PLLA polymer, crystallisation of
HA and calcite was evident on composite 45S5 BG® -PLLA scaffolds
on X-ray diffraction analysis. Larger 45S5 BG® content, especially
30e50%, led to rapid HA crystallisation on the surface of composite
scaffolds. However, degradation of composites containing 50% 45S5
BG® occurred rapidly within 7 days in vitro. Therefore, it was
concluded that composites with 30% 45S5 BG® seemed to exhibit
the best balance between bioactivity and stability at least during
the ﬁrst weeks of immersion in contact with SBF. In vivo analysis of
the 30% 45S5 BG® -PLLA composite within rabbits also found strong
osseointegration a month after implantation.
Westhauser et al. investigated the osteoinductive properties of
different polymer coated 3D-45S5 BG® scaffolds seeded with hu-
man MSCs (hMSCs) in vivo [166]. 45S5 BG® scaffolds were dip-
coated with either gelatin, cross-linked gelatin, or poly(3-
hydroxybutyrate-co-3-hydroxyvalerate). After seeding with
hMSCs, the scaffolds were implanted into immunodeﬁcient mice.
Histomorphometry and micro-computed tomography (micro-CT)
was then performed after 8 weeks (Fig. 9). Although bone forma-
tionwas detected in all scaffolds, gelatin-coated 45S5 BG® scaffolds
performed the best overall with further studies required to fully
evaluate their potential for BTE on a larger scale.
Murphy et al. utilised 3D extrusion bioprinting to create a
composite polycaprolactone (PCL)/BG scaffold containing human
adipose-derived stem cells (ASCs). Borate glass and PCL were
initially dissolved in organic solvent to create a pastewith printable
viscosity. ASCs suspended in Matrigel were then co-printed via a
second syringe as droplets into the PCL-BG scaffold. Degradation of
the scaffolds in SBF was analysed, with 23.2 ± 4% weight loss due to
controlled BG dissolution found at 14 days. Cell viability after 24 h
was 70 ± 10% and after 7 days was 58 ± 11%. Scaffold pore sizes
ranged from 100 to 300 mm, making it ideally suited for BTE.
Bioactivity of the BG component was also seen, with formation of
HA crystals witnessed on the scaffold surface. This study therefore
demonstrated the potential for solvent-based 3D bioprinting to
fabricate a scaffold containing cells and BG-polymer composites for
BTE applications [167].
Baino et al. utilised a sponge template method involving sin-
tering to fabricate a silicate-based glass-ceramic scaffold. Their
intention was to create a scaffold capable of repairing large defects
in load-bearing bones. Total scaffold porosity was 56%, with pore
sizes ranging from 100 to 500 mm on micro-CT analysis. When
tested under compression, the scaffolds had an elastic modulus of
380 MPa and a compressive strength of 18 MPa [168].
Eqtesadi et al. utilised the 3D printing technique of robocasting
to fabricate 13e93 BG scaffolds with a pore size of ~230 mmand 51%
overall porosity. The scaffolds unfortunately showed brittle char-
acteristics with a compressive strength of 86 MPa and a modulus of
rupture of 15 MPa. PCL was therefore added to the BG to create
composite scaffolds, as an attempt to address the brittleness and
Fig. 9. Micro-CT and histomorphic analysis showing new bone formation in polymer-coated BG scaffolds implanted in mice for 8 weeks [166].
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ﬂexural strength of scaffolds. Whilst compressive strength of the
scaffolds was maintained, brittleness was signiﬁcantly reduced as
13e93/PCL composite scaffolds were able to survive large stains
[169].
BGs have also been used to improve the surface bioactivity of 3D
printed b-TCP scaffolds, with promising results found. Zhang et al.
spin-coated mesoporous (pores with diameters between 2 and
50 nm) bioactive glass (MBG) nanoparticles onto porous b-TCP
scaffolds to create a 100 nm layer of MBG on scaffold surfaces [170].
This resulted in a hierarchical pore structure with both MBG mes-
opores and BGmacropores present in the scaffold. The compressive
strength and mineralization of MBG-b-TCP scaffolds were also
signiﬁcantly enhanced as compared to b-TCP scaffolds without the
MBG nanolayer. Culture of human umbilical vein endothelial cells
(HUVECs) found increased cell attachment, viability and angiogenic
gene expression compared with conventional BG-modiﬁed b-TCP
(BG-b-TCP) and pure b-TCP scaffolds. Furthermore, MBG-b-TCP
scaffolds signiﬁcantly enhanced the formation of new bone in vivo
as compared to BG-b-TCP and b-TCP scaffolds.
The majority of drugs used in clinical practice are measured on
the nanometre scale and can therefore be introduced into meso-
porous bioglass structures, potentially improving bioactivity and
drug delivery [171]. Jiang et al. coated mesoporous BG scaffolds
with amides, with subsequent gentamicin loading onto the scaffold
mesoporous surface achieved. As a result, higher gentamicin
loading and longer drug release were achieved in vitro compared to
BG scaffolds that had not undergone amination. In vitro bioactivity
was also improved, with increased formation of surface hydroxy-
apatite found after soaking in simulated body ﬂuid for 3 days
(Fig. 10) [172]. MBGs have been utilised by several other studies to
create composite scaffolds with increased bioactivity
[170,173e175].
BG composites have also been used as injectable cements in
some studies, with antibiotic [176], natural polymer [177] and
synthetic polymer [178] composites found to be cell friendly and
capable of treating in vivo bone and cartilage defects. Zhang et al.
prepared a strontium-doped, borate bioactive glass (BBG)-chitosan
composite cement and evaluated in vitro and in vivo performance
[179]. The Sr-BBG cement showed the valuable ability to set in situ
(initial setting time ¼ 11.6 ± 1.2 min) and a compressive strength of
19 ± 1 MPa. The Sr-BBG cement was also found to enhance the
proliferation and osteogenic differentiation of hBMSCs in vitro
when compared to a similar cement composed of chitosan-bonded
BBG particles without Sr. The cement was then injected into rabbit
femoral condyle defects, with new bone formation supported by
the Sr-BBG cement. It would therefore appear to be a promising
treatment for treating irregularly shaped bone defects through
minimally invasive surgery.
4.4. Polymers
Use of natural polymers in scaffolds has attracted great interest
within BTE due to favourable properties including ductility,
biocompatibility and biodegradability. As a further beneﬁt, natural
polymers often contain biofunctional molecules on their surface
that can aid cell attachment, integration and differentiation on
scaffolds. Naturally occurring polymers that have been investigated
in BTE include collagen, silk, alginate, chitosan and hyaluronic acid.
However, use of naturally occurring polymers can also be subject to
limitations including presence of pathogenic impurities such as
endotoxin [180], lack of tuneability of degradation rates and
degradation related inhibition of local cells. Mechanical properties
of natural polymers are also suboptimal for BTE, although cross-
linking of polymers can enhance structural properties [181e183].
Synthetic polymers that have been deployed in BTE include
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(caprolactone)
(PCL) and poly(ethylene glycol) (PEG). Co-polymers including pol-
y(lactic-co-glycolic acid) (PLGA) have also been used. Synthetic
polymers can be created with tailored pore size, porosity, degra-
dation rate and mechanical strength as required [184e187]. How-
ever, they are often hydrophobic and lack cell recognition sites,
limiting application without secondary modiﬁcation to improve
bioactivity [188,189]. Synthetic and natural polymers in general
have relatively poor load bearing capacity when used alone, with
low elastic moduli compared to metallic and ceramic compounds
[190,191]. However, the mechanical requirements of BTE scaffolds
are complex, with compressive, tensile and fatigue properties all
required for load bearing [192].
One approach that has proved popular in addressing these
limitations is the combination of polymers with bioceramics or
bioglasses to produce composite scaffolds. Most often, bioceramics
or bioglasses are added as a coating or ﬁller to a polymer matrix to
improve bioactivity in addition to ramifying mechanical properties
[180,193,194]. Porosity can also be added to composite polymer-
ceramic scaffolds with varying levels of precision using tech-
niques including 3D printing [80] and electrospinning [127,195].
These techniques are capable of depositing material with gaps
between ﬁbres to allow interconnectivity. Alternatively, porogens
Fig. 10. SEM images of the amine-coated MBG before (A) and after (B) soaking in SBF. Formation of a crystalline HA layer was conﬁrmed on Fourier transform infrared spectroscopy
[172].
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can be incorporated into the structure before being dissolved out,
or chemically triggered to release gas, to create pores [196e198].
Combining use of porogens with techniques such as 3D printing
during manufacturing can increase micro and macroporosity.
Polymer-based scaffold surfaces have also been secondarily
chemically treated to increase microporosity, through use of
organic solvents [199,200]. Scaffold performance can also be
increased by surface modiﬁcation with bioactive substances
including growth factors and surface ligands to aid cell adhesion
and proliferation [121,193,201e203].
4.4.1. Collagen ebased composite scaffolds
Amongst the natural polymers used in bone tissue engineering,
collagen is perhaps the most frequently adapted into scaffolds.
Collagen composes 90% of the total weight of bone extracellular
matrix proteins and is therefore a logical choice for inclusion in a
composite BTE scaffold. Although there are approximately twenty-
nine known types of collagen, type I collagen has been used most
frequently within BTE due to the lack of immune reactivity asso-
ciated its use [204]. As part of the normal ECM it is inherently
biocompatible, biodegradable and can stimulate cell proliferation
and differentiation [205,206]. Furthermore, the mechanical and
degradation properties of collagen can be tailored through the
process of crosslinking [207]. However, in common with other
natural polymers, collagen has mechanical properties that are
insufﬁcient for creating a load-bearing scaffold [208]. It is therefore
often combined with more robust materials within BTE to create
composite scaffolds. As the major inorganic component of bone,
hydroxyapatite (HA) has frequently been combined with collagen
in composite scaffolds.
Villa et al. developed a collagen-HA (Col-HA) scaffold through a
co-precipitation and freeze casting process [209]. The scaffold
created had a high degree of permeability suitable for cell inﬁl-
tration, attachment and osteogenesis with 99% interconnectivity of
pores. Mouse bone marrow derived mesenchymal stem cells
(BMSCs) were seeded onto the scaffold and seen to bewell attached
after 12 h in vitro culture. Subsequently the scaffolds were
implanted into a mouse calvarial defect. After three weeks in vivo,
near complete ﬁlling of the calvarial defects with bone on radio-
graphic andmineralization analysis was found. After several weeks,
host matrix metalloproteinase breakdown of collagen had to led to
scaffold degradation occurring. By contrast, Marcacci et al. previ-
ously found that a pure HA scaffolds failed to degrade 6 years after
insertion into 4 patients with long bone defects [210]. However,
compliant mechanical properties of the Col-HA scaffold were
observed making it perhaps best suited for non-load bearing ap-
plications such as craniofacial repair [209]. Alternatively, it could be
used to aid treatment of a complex fracture in the same way that
bone substitutes or bone grafts are commonly used, in combination
with mechanical ﬁxation [211].
Calabrese et al. also demonstrated the osteoinductive potential
of a type 1 collagen (30%) -HA (70%) scaffold. The scaffold in this
instance was prepared by a freeze casting process, with the addi-
tion of a magnesium to create bioactiveMg-doped HA (MHA) nano-
crystals. Human MSCs isolated from adipose tissue were seeded
onto the scaffold and cultured in vitro in the absence of speciﬁc
osteogenic inducing factors. Analysis through quantitative PCR and
immunohistochemistry at up to 8 weeks demonstrated osteogenic
differentiation of MSCs. This study therefore showed that the
scaffold materials alone could trigger osteogenic differentiation of
MSCs, with extracellular matrix production, gene expression and
mineralization analysis all demonstrating the osteoinductive po-
tential of the scaffold. Nevertheless, osteogenic differentiation was
found to be signiﬁcantly accelerated with the addition of osteo-
genic factors to the culture medium [123]. In vivo analysis was then
performed of the scaffold in mice, with ectopic osteoinductive and
angiogenic performance of the Col-MHA composite scaffold
compared to a pure collagen scaffold. Bone augmentation and
angiogenesis were found to spontaneously occur into the com-
posite Col-MHA scaffold, with recruitment of host cells into the
structure. The Col-MHA scaffold performed signiﬁcantly better
than the collagen alone scaffold, with less ﬁbrotic tissue and more
osteogenic tissue deposited at up to 16 weeks [212].
Grigolo et al. also utilised a scaffold composed of type 1 collagen
and Mg doped-HA. The scaffold was designed to be biomimetic,
with three distinct layers included to replicate the cartilaginous,
tidemark and subchondral layered structure of articulating bone
[213,214]. The cartilaginous layer was composed of purely type 1
collagen; the intermediate layer type I collagen (60%) and Mg-HA
(40%); and the sub-chondral layer type I collagen (30%) and Mg-
HA (70%). The scaffold was manufactured by combining a sinter-
ing and a freeze-drying technique, to obtain an integrated mono-
lithic composite. Human MSCs (hMSCs) were seeded onto the
single layers of the composite scaffold individually, and onto the
integrated composite scaffold. Cells were then grown in either
chondrogenic or osteogenic media for comparison. Immunostain-
ing conﬁrmed chondrogenic differentiation of hMSCs in the
collagen-only cartilaginous layer when using chondrogenic media.
Chondrogenic differentiation did not occur in the Mg-HA bone
layer despite use of chondrogenic media. Immunostaining also
conﬁrmed osteogenic differentiation of hMSCs in both layers con-
taining Mg-HA, and inﬁltration into the cartilaginous layer when
osteogenic mediawas used, but this did not occur in the presence of
chondrogenic media. Therefore, the processes of osteogenic and
chondrogenic differentiation tended to depend mainly on the
media used for culture, rather than the biomaterial composition in
this study [215] (Fig. 11). Human bone marrow concentrate was
then used in place of hMSCs on the three-layered scaffold in a
Fig. 11. Photograph of the biomimetic scaffold showing the external appearance and layered structure; SEM images showing the interface between scaffold layers [215].
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further study. Having found a lack of osteogenesis in the cartilagi-
nous layer, and a similar lack of chondrogenesis in the bone layer,
they decided to induce chondrogenic differentiation only in the
cartilaginous layer and osteogenesis in the composite layer (type I
collagen (60%) and Mg-HA (40%)) and bone layer (type I collagen
(30%) and Mg-HA (70%)). After 52 days in vitro, cell viability
remained high and differentiation of cells down both the chon-
drogenic and osteogenic pathways was demonstrated on histo-
logical and immunohistochemical analysis. This biomimetic, nano-
composite material would therefore appear to offer a potential
option for treating osteochondral lesions. In combination with
patient-derived bone marrow concentrate, chondrogenic and
osteogenic areas could be combined into the same scaffold to offer a
“one step” transplantation procedure for osteochondral defects
[216].
Kane et al. looked to improve upon the mechanical properties of
collagen-HA scaffolds previously described by modifying the
freeze-drying process most commonly used in their manufacture
[217e219]. Attempting to improve scaffold porosity andmechanical
strength, they used compression moulding to combine HA, parafﬁn
micro-spheres and concentrated collagen ﬁbrils. The parafﬁn
micro-spheres were then leached out, acting as porogens, and the
collagenwas chemically cross-linked [126]. Interconnected pores of
300e400 mm in size with walls 3e100 mm thick were found on
micro-CT analysis, with overall 85e90% porosity. This is signiﬁcant,
as scaffold pores greater than 300 mm have been shown to be
favourable for osteointegration [160]. Mechanical testing found
scaffolds with 60% HA to exhibit fully elastic deformation upon
loading to 50% compressive strain, maintained over greater than
100 000 cycles. Compared to Col-HA scaffolds created through
freeze-drying, the compressive modulus of the scaffold created in
this study was a magnitude greater at approximately 1 MPa. These
properties make the scaffold well suited to clinical application, as
elastic deformation would potentially facilitate surgical handling
and manipulation, whilst the compressive modulus demonstrated
would potentially facilitate a degree of load bearing. In vitro
bioactivity was investigated by seeding murine adipose derived
stromal cells (mASCs) onto the scaffolds and culturing in osteogenic
media. After 14 days, signiﬁcant increases in ALP activity were seen,
with complete inﬁltration of the scaffold by mASCs. HA containing
scaffolds showed vastly superior bioactivity compared to collagen-
only scaffolds, in keeping with other studies [180,220,221], with
increased osteogenic differentiation and ALP levels found. How-
ever, increasing HA content beyond 40% had no signiﬁcant beneﬁt.
In vivo angiogenesis and osteogenesis in 40% HA scaffolds was then
evaluated by implanting acellular scaffolds subcutaneously in mice
for 8 weeks. In vivo the scaffold was shown to be conducive to the
inﬁltration and differentiation of endogenous cells, with osteo-
genesis and angiogenesis observed on histological analysis, sug-
gesting the scaffold is osteoinductive. Therefore, the collagen-HA
scaffolds in this study would appear to have potential for clinical
use as a synthetic bone graft replacement, given their superior
mechanical properties to scaffolds prepared by freeze-drying and
favourable osteoinductive and angiogenic properties.
Meagher et al. investigated the impact of HA volume fraction on
the in vivo performance of Col-HA scaffolds produced by
compression moulding. Acellular collagen scaffolds containing 0,
20, and 40 wt% HA were implanted subcutaneously for up to 12
weeks in mice. Endogenous cell inﬁltration after 6 weeks was
increased in scaffolds containing HA versus collagen alone. Angio-
genesis, remodelling of the original scaffold matrix, mineralization
and osteogenic gene expressionwas evident in scaffolds containing
HA, but not observed in pure collagen scaffolds. Increasing scaffold
HA content was found to be directly correlated with improved
vascularity, cell density, matrix deposition and mineralization on
histological and micro-CT analysis. It would therefore seem that HA
promotes the recruitment and differentiation of endogenous cell
populations, leading to angiogenic and osteogenic activity in
collagen scaffolds. Contrastingly, collagen scaffolds exhibited no
matrix deposition, mineralization, osteogenic gene expression and
a signiﬁcantly lower cell inﬁltration density [222].
Perdisa et al. demonstrated the osteoinductive potential of Col-
HA scaffolds further in a prospective clinical study involving pa-
tients with patellar osteochondral defects [223] (Fig. 12). Cell-free
Col-HA scaffolds were implanted into knee or patellar osteochon-
dral lesions, with MRI imaging performed 24 months following
surgery. The composite scaffold in this study utilised the same
three-layered approach as used by Grigolo et al. [215]; the carti-
laginous layer was made of type I collagen with a smooth surface;
the intermediate layer had a combination of type I collagen (60%)
and HA (40%); and the lower layer was a mineralised blend of type I
collagen (30%) and HA (70%), mimicking subchondral bone
composition. Patient functional outcome scores improved signiﬁ-
cantly at 12 and 24 months follow up, with MRI showing complete
ﬁlling of the cartilage in 87.0% of the lesions, complete integration
of the graft in 95.7% of lesions, and intact repair tissue surface in
69.6% of patients. However, osteophytes or more extensive bony
overgrowth was also documented in.8% of the patients, though no
correlation was found between MRI ﬁndings and clinical outcome
[223].
4.4.2. Chitosan e based composite scaffolds
Chitosan (CS) is a polysaccharide normally found in the shell of
crustaceans including crabs, lobsters and shrimp. As a versatile,
semi-synthetic polymer it has favourable biocompatibility and
biodegradability in addition to antibacterial and bioadhesive
characteristics [197,224,225]. Within BTE chitosan has been com-
bined with a number of materials in scaffolds including calcium
phosphate [226], calcium sulfate [227], hydroxyapatite [228] and
other natural polymers including silk [229e231].
Microparticle-based chitosan scaffolds have been produced by
several groups [106,232e234]. Jiang et al. produced a composite CS/
poly(lactic acid-co-glycolic acid) (CS/PLAGA) sintered microsphere
scaffold, functionalizing the scaffold surface further with heparin
molecules [235]. Scaffolds had a mean pore size of 172 mm, with a
compressive strength in the region of trabecular bone. Mechanical
testing showed that heparinization of chitosan/PLAGA scaffolds did
not signiﬁcantly alter scaffold mechanical properties or porosity.
Osteoblast-like cells were observed to proliferate faster on CS/
Fig. 12. Osteochondral scaffold, sized and press-ﬁt into a patella defect. Adapted from
Perdisa et al. [223].
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PLAGA scaffolds as compared to pure PLAGA scaffolds. Furthermore,
it was shown that the presence of CS on microsphere surfaces
increased the ALP activity of the cells cultured on the composite
scaffolds and up-regulated gene expression of osteopontin and
bone sialoprotein. This study therefore demonstrated the potential
of functionalized chitosan/PLAGA scaffolds.
Nano-ﬁbre based composite chitosan scaffolds have also been
investigated within BTE, fabricated using methods such as wet
spinning [236,237] and electrospinning [238] and including ma-
terials such as silicon [239] and nano-hydroxyapatite (nHA) [240].
However, electrospinning of CS can be difﬁcult and scaffold stability
inside aqueous solutions is unreliable. Secondary crosslinking with
agents such as poly(ethylene oxide) (PEG) and blending with other
polymers such as silk, collagen and PCL to create composites can
however signiﬁcantly reduce the degradation rate of CS in elec-
trospun scaffolds and improve bioactivity [241].
CS has also been combined with collagen and bone morpho-
genic protein (BMP) in composite scaffolds, with in vivo perfor-
mance in dog and rabbit models analysed [31,242].
Shi et al. encapsulated BMP in poly-L-lactide-co-glycolide
(PLGA) biodegradable microspheres, before dispersing them in a
chitosan/collagen composite scaffold. The scaffolds were implanted
in dog mandibles for 4 weeks, with histologically enhanced bone
formation found in BMP/PLGA microsphere loaded scaffolds
compared to control chitosan/collagen scaffolds also containing
BMP. It was therefore concluded that sustained release of BMP from
microspheres was more effective in inducing implant osseointe-
gration compared to BMP bound to scaffolds.
Hou et al. prepared chitosan microspheres (CMs) and combined
them with an absorbable collagen sponge with freeze-drying per-
formed, to achieve controlled-release of BMP. The BMP-loaded
composite scaffolds were implanted into 15 mm radius defects of
rabbits and the bone-repair ability was evaluated. Defects were
found to be bridged by new bone as early as 4weeks, with complete
healing and recanalization of the bone-marrow cavity at 12 weeks
evident on X-ray and histological analysis. These results demon-
strated that the composite CS-Col scaffold is a promising carrier of
BMP-2 for the treatment of segmental bone defects [242].
Wu et al. developed a novel, composite scaffold of poly(L-lactic
acid)/nHA/Alendronate-loaded chitosan microspheres (CS-ALs)
with promising application for drug delivery and BTE demonstrated
in vitro and in vivo [243] (Fig. 13). Alendronic (AL) acid has been
used in an increasing number of BTE studies, with known proper-
ties including potent osteoinduction and inhibition of bone
resorption [244,245]. Using a room temperature moulding/particle
leaching method [246], followed by compression moulding, porous
scaffolds of PLLA/nHA/CS-AL were prepared with the concentra-
tions of CS/nHA-AL ranging from 0 to 20%. Porous PLLA/nHA scaf-
folds with only PLLA and nHA were also produced for use as
controls. SEM found the scaffolds to exhibit a homogeneously
interconnected porous structure, with the pore diameters of
150e250 mm. Scaffolds with 10% of CS/nHA-AL were then analysed
in vitro, having been found to possess the most favourable drug
release, degradation and mechanical properties. Culture of rabbit
adipose stem cells (ASCs) found rapid cell proliferation and ECM
production after 5 days, with no apparent cytotoxicity seen. Growth
in osteogenic media led to signiﬁcantly increased ALP activity and
calcium deposition, with CS-AL scaffolds containing CS/nHA-AL
having signiﬁcantly better results than control scaffolds. Scaffolds
containing 10% and 0% CS-ALs were then implanted into a rabbit
bone defect model to further evaluate in vivo bone regeneration.
Bone defects were healed with new bone formation seen during
4e8 weeks of implantation. New bone formation was signiﬁcantly
higher in CS-ALs (10%) group when compared with CS-ALs (0%), an
effect that increased with time on histological analysis. Sustained
release of AL was also found for up to 30 days. This study therefore
showed promising application of CS-AL microsphere loaded (10%)
scaffolds for both drug delivery and bone tissue engineering.
4.4.3. Hyaluronic acid e based composite scaffolds
Hyaluronic acid (HLA) is a natural glycosaminoglycan found
widely throughout connective, epithelial and neural tissues. As one
of the chief components of the extracellular matrix, HLA contrib-
utes signiﬁcantly to cell proliferation and migration. It typically has
a very large molecular weight and has been adapted into attempts
at both hard and soft tissue engineering, particularly as a hydrogel
(as discussed in the later hydrogel section) [247,248]. The me-
chanical properties of HA can be readily improved through pro-
cesses such as crosslinking [79,249], whilst it is naturally
viscoelastic, biodegradable and biocompatible, making it an ideal
material for BTE [250].
HLA has been implemented in composite scaffolds by several
groups. Kim et al. recently looked to combine favourable properties
of multiple materials in fabricating a graphene oxide (GO)eChito-
san (CS)eHyaluronic acid (HLA) based bioactive composite scaffold
also containing an osteogenesis-inducing drug simvastatin (SV)
[251]. Interestingly, SV is capable of initiating osteoblast differen-
tiation of human adipose derived stem cells (hADSCs) and is well
known for its property to enhance bone morphogenic proteins
(BMPs). In fact, there are several examples in the literature of SV
being used in composite scaffolds and injectable gels for bone
regeneration, with improved osteogenesis seen [252e258]. The SV
Fig. 13. Comparison of CS-ALs (10%)-implanted group to CS-ALs (0%) found signiﬁcantly higher new bone formation, a ﬁnding which increased with time. SEM images of the CS-AL
scaffold, with black arrows indicating the PLLA/nHA matrix and the white arrow indicating a CS/nHA-AL microspheres [243].
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loaded GOeCSeHLA scaffold in this study was prepared in brief by
mixing dissolved CS and HLA, with GO added through continuous
stirring to create a composite blend, before a freezing and lyophi-
lisation step to add SV was performed. Finally, the obtained com-
posite scaffolds were cross-linked with N,N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide (EDC). Electron mi-
croscopy found the scaffolds to have an interconnected porous
morphology. The addition of GO also resulted in less swelling and
ultimately contributed to enhanced structural integrity of the
scaffold. However, introduction of GO also caused a 35% reduction
in porosity of the GOeCSeHLA scaffold. MC3T3 (Osteoblasts) cells
were seen to adhere and proliferate better on SV loaded
GOeCSeHLA scaffolds throughout 48 h of in vitro analysis. This was
reﬂected by signiﬁcantly higher scaffold mineralization being
found in SV loaded scaffolds after 14 days of analysis. Overall, the SV
loaded GOeCSeHLA scaffold appeared to offer a successful option
for BTE, with the addition of SV signiﬁcantly accelerating bioactivity
and osteogenesis.
Jing et al. also combined HLA and CS in a porous scaffold for
bone tissue engineering [259]. Mixing CS and HLA together as liq-
uids, they used a freeze-drying approach to form porous, 3D scaf-
folds. By performing a further cross-linking step, the elastic
modulus and structural integrity of the scaffold was increased.
Stem cell colonisation and proliferation within the scaffold was
demonstrated by DNA assays and confocal imaging. Correia et al.
also used a freeze-drying processed to prepare composite scaffolds
of chitosan and HLA, though directed their scaffolds at cartilage
tissue engineering. Within this study incorporation of HLA
enhanced cartilage ECM production, chondrocyte proliferation and
cell adhesion to scaffold surfaces [260].
Kim et al. combined HLA and collagen in a scaffold directed at
regenerating cartilage [261]. The hybrid scaffolds were prepared by
adding 0.1, 0.3 or 0.5 wt% collagen to HLA. The HLA was then
crosslinked with ethylene glycol diglycidyl ether, followed by a
freeze-drying process. The resulting composite scaffolds had a
three-dimensional structure with interconnected pores and
showed an increase in tensile strength with increasing collagen
concentration. The degradation time of the hybrid scaffolds in vitro
increased with increasing collagen concentration. In vitro chon-
drocyte growth on the scaffolds was also improved by increasing
collagen concentration over 2 weeks in culture. Furthermore,
glycosaminoglycan (GAGA) concentration in the hybrid scaffolds
was higher than in pure HLA scaffolds. These composite scaffolds
would therefore seem to have potential for in vivo cartilage
regeneration.
HLA has also been used as a delivery agent to improve bioac-
tivity in bone substitute materials. Chang et al. investigated
whether the use of HLA as an aqueous binder of hydroxyapatite/
beta-tricalcium phosphate (HA-bTCP) particles could reduce the
amount of bone graft needed and increase ease of graft handling in
clinical situations [262] (Fig. 14). HA/bTCP was loaded into cross-
linked HLA to form a novel HLA/HA-bTCP composite, which was
then injected into rabbit skull defects in vivo. Histological and
micro-CT analysis found that HLA allowed bone regeneration to be
maintained evenwhen HA-bTCP particle numbers were reduced. In
fact, compared to the control scaffold, HLA/HA-bTCP samples had
1.7 times larger bone formation after 2 weeks. Overall, the addition
of HLA to bone grafts not only promoted osteoconduction but also
improved handling characteristics in clinical situations.
4.4.4. Silk - based composite scaffolds
Silk ﬁbroin (SF) is a natural protein-based polymer mainly
produced by silkworms and spiders. SF possesses several charac-
teristics desirable for use in bone tissue engineering, including
biocompatibility, low immunogenicity, limited bacterial adhesion,
tuneable biodegradability, mechanical integrity and the ability to
support the differentiation of mesenchymal stem cells along the
osteogenic lineage [263e265].
McNamara et al. developed a new technique in fabrication of
porous HA-silk scaffolds. Firstly, they mixed silk together with HA
powder before addition of silk macroporogens. The mixtures were
then sintered, with silk acting as a sacriﬁcial polymer creating
porosity. The resulting silk-HA scaffolds could be moulded into
large, complex shapes, and further machined post-sinter to
generate speciﬁc three-dimensional geometries. Scaffolds also
supported bone marrow-derived MSC attachment and prolifera-
tion, with no signs of cytotoxicity [266].
Kweon et al. compared the performance of HA-coated silk
scaffolds and HA-coated collagen scaffolds. They implanted both
scaffold variants into rat tibias, with histological analysis of bone
formation around the scaffolds performed after 6 weeks in vivo.
They found that coating silk based scaffolds with HA promoted
bone regeneration and bone to scaffold contact, with superior re-
sults demonstrated compared to HA-coated collagen scaffolds
[267].
Silk has also been used to coat BTE scaffolds, with encouraging
results found. In one study, PCL nanoﬁbers were coated with silk
and combined with biphasic calcium phosphate (BCP) in a com-
posite scaffold [268]. Addition of silk-coated PCL nanoﬁbers
improved scaffold compressive strength (from 0.07 MPa for BCP to
Fig. 14. Micro-CT images of the artiﬁcial skull defects after 4 weeks, showing signiﬁcant bone regeneration in HLA/HA-b-TCP composites (B) compared to control (A).
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0.42 MPa), elastic modulus (from 5 MPa for BCP to 25 MPa), and
bioactivity whilst also preserving porosity (85%) and inter-
connectivity (99%). Furthermore, osteoblast proliferation and dif-
ferentiation rates were increased in the BCP/PCL-silk scaffolds
compared to that in the BCP/PCL and BCP scaffolds. Jaio et al. also
modiﬁed BCP scaffolds with silk, applying multiple coatings to the
scaffold surface. In doing so they managed to signiﬁcantly enhance
scaffold mechanical performance, with properties comparable to
native bone tissue found. Once again osteogenesis by hMSCs was
found to be positively inﬂuence by silk over an extended period in
culture [269].
Cao et al. used a HA-mineralised silk to mechanically reinforce
an injectable bone cement [270]. In this study, a hydroxyapatite
(HA)esilk ﬁbroin (SF) complex was synthesised through a co-
precipitation method and added to an injectable CPC/SF compos-
ite. The compressive strength of the three-component composite,
CPC/HAeSF/SF, kept increasing as HAeSF content was increased to
3 wt%. The setting time of CPC/HAeSF/SF composites also
decreased as a function of HAeSF content, with no apparent effect
on injectability. Furthermore, the CPC/HAeSF/SF composites
showed good biocompatibility both in vitro and in vivo. It was
therefore suggested that the composite could hold promise for
orthopaedic applications, including serving as ﬁller materials for
minimally invasive surgeries to treat vertebral fractures.
In a further study, attempts were made to enhance the me-
chanical properties of electrospun SF scaffolds by uniformly
dispersing hydroxyapatite (HA) nanoparticles within SF nanoﬁbers
[271]. Addition of HA content up to 20 wt% increased the me-
chanical properties of the composite scaffolds, while further in-
creases above 20wt% disrupted the polymer chain networks within
SF nanoﬁbers and weakened overall mechanical strengths.
4.4.5. Synthetic polymer composites
Use of natural polymers such as type I collagen in composite
scaffolds has many advantages, including increased ease of enzy-
matic degradation, biocompatibility and improved scaffold simi-
larity to natural bone extra-cellular matrix. However, natural
polymers such as collagen used within scaffolds can have weak
mechanical properties [42,272e274]. Signiﬁcant research has
therefore looked to optimise and improve scaffold properties by
developing hybrid synthetic polymer/ceramic scaffolds for bone
tissue engineering. Synthetic polymers that have been used
frequently within BTE include polycaprolactone (PCL), polylactic
acid (PLA), polyglycolic acid (PGA), and copolymers of PLA-PGA
(PLGA). These poly(a-ester)s have key characteristics of being
biodegradable, nontoxic and biocompatible [275e277].
4.4.6. Polycaprolactone (PCL) e based composite scaffolds
Polycaprolactone has beenwidely used in BTE for the fabrication
of 3D scaffolds. Advantages of this polyester include biocompati-
bility, relatively slow degradation rate, less acidic breakdown
products in comparison to other polyesters and potential for load-
bearing applications [191,278e280]. In terms of hard tissue engi-
neering, the high mechanical strength and slow degradation rate of
PCL are particularly advantageous characteristics, potentially
allowing load-bearing whilst native tissue gradually ossify a BTE
scaffold [281]. However, due to the poor cellular adhesion proper-
ties of PCL, numerous attempts have been made to create PCL
composites with improved bioactivity [282,283].
Kim et al. demonstrated the potential of PCL/alginate composite
scaffolds, showing superior in vitro results in 3D printed PCL/algi-
nate composite scaffolds compared to pure PCL scaffolds [284].
Alginates have desirable characteristics for use in 3D scaffold
fabrication, including biocompatibility, low cost, controlled degra-
dation and rapid gelation in the presence of calcium ions
[224,285,286]. However, they also have poor mechanical properties
and excessive hydrophilicity, making it difﬁcult to control scaffold
structure and shape [287,288]. Kim et al. therefore attempted to
combine the favourable properties of alginate and PCL by melting
PCL and alginate powders together at 130 C, before extruding the
melted composite through a 250-mm nozzle to create a 3D scaffold.
Compared to a pure PCL scaffold fabricated by the same method,
PCL/alginate scaffolds showed increased osteoblast cell viability,
calcium deposition, ALP activity and greater cell-seeding efﬁciency
over 7 days in culture.
Kim et al. used a combination of 3D printing, electrospinning
and a physical punching process to create composite PCL/alginate
constructs with nanoﬁbrous content and improved mechanical
strength. Electrospun layers of PCL/alginate were sandwiched by
layers of micro-sized PCL struts; the ﬁnal scaffold was then
punched to create micro-sized pores travelling through the
consecutive layers of electrospun and 3D printed material (Fig. 15).
Compared to pure PCL scaffolds, PCL/alginate composite scaffolds
showed signiﬁcantly enhanced cell viability at 7 days, ALP activity
and calcium deposition at 14 days and greatly increased water
absorption due to the improved hydrophilicity contributed by the
scaffold alginate content [271].
Hydroxyapatite has also been combined with PCL by several
groups attempting to create more bioactive, composite scaffolds for
BTE. Gonçalves et al. utilised silicon-doped nanocrystalline HA, PCL,
and carbon nanotubes in 3D printed composite scaffolds [124]. In
using three distinct materials, they hoped to merge properties
favourable to bone regeneration including biocompatibility,
Fig. 15. PCL/Alginate scaffold fabrication method. (A) 3D printing of micro-sized PCL struts (B) electrospinning of PCL/alginate onto PCL struts (C) punching process to create micro-
sized pores in ﬁnal PCL/alginate (PAS-S) scaffold. Adapted from Kim et al. [271].
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osteointegration ability and biodegradability [193,289,290]. Nano-
crystaline silicon-doped HA was chosen as a ceramic material due
to the chemical composition being comparable to the inorganic
part of native bone. It has also been shown that the in vivo bioac-
tivity of silicon-doped HA (SiHA) is signiﬁcantly improved
compared to pure HA, with enhanced bone apposition, bone in-
growth and cell-mediated degradation found on SiHA implants
[291,292]. Carbon nano-tubes (CNTs) have been shown to inﬂuence
and enhance cell differentiation and adhesion, by increasing elec-
trical stimulation to cells [293e296]. PCL was incorporated into the
scaffold to add ductile properties to the ceramic SiHA. Additionally,
PCL has a relatively low melting temperature (approximately
60 C), making it ideal for 3D printing [297,298]. To combine the
materials, PCL and HA were dissolved independently in dicho-
loromethane. CNTs were then added to the HA in solution, and the
PCL solution was then added to the HA-CNT suspension. The slurry
was mixed and slowly heated to allow the dichloromethane to
evaporate until a suitable viscosity for 3D printing was achieved.
Scaffolds of differing CNT content were then printed, with CNT
content ranging from 0 to 10%. Scaffolds containing 10% CNTs had
signiﬁcantly greater apatite deposition and osteoblast-like cell
adhesion after 6 days in vitro. Additionally, electrical resistance of
the scaffolds decreased as CNT content increased. This would sug-
gest that CNTs have beneﬁcial effects on cell function through
modifying surface charge, as suggested by previous studies
[293e295]. In terms of the mechanical properties, scaffold load-
bearing capacity was improved by a CNT content of up to 0.75%.
Beyond 2% CNT content, there was a clear detrimental effect on
compressive strength. Nevertheless, compressive strength values
for pure PCL-SiHA and PCL-SiHA scaffolds with CNT content up to
0.75% were comparable to those found in the literature for
trabecular bone [299]. Morphologically, the scaffolds were found to
have interconnected pores with sizes from 450 to 700 pm. Overall,
the scaffolds with 2% CNTs offered the best combination of me-
chanical behaviour, cell viability and electrical conductivity.
Jakus et al. also utilised organic solvents to create a composite
HA-PCL biomaterial, described as “hyperelastic bone,” or “ HB.” HA
powder and either PCL or PLGA were added to a trisolvent mixture
of excess dichloromethane (DCM), 2-butoxyethanol (2-Bu) and
dibutylphthalate (DBP) [300]. The resulting solutions were then
stirred in an open environment to allow solvent evaporation, until a
viscosity ideal for 3D printing was reached. The synthetic com-
posites composed of 90% HA and either 10% PCL or PLGA could be
rapidly 3D printed (up to 275 cm3/hour) from room temperature
extruded liquid inks. Mechanical testing of HB found elastic prop-
erties; although not as elastic as their pure polymer counterparts,
both HA-PLGA and HA-PCL versions of HB retained a high degree of
elasticity, capable of undergoing 36.1 ± 4.3% and 61.2 ± 6.4% strain
and having similar tensile elastic moduli of 4.3 ± 0.4 MPa and
10.3 ± 1.3 MPa, respectively (Fig. 16). To examine biocompatibility
in vivo, HA-PLGA scaffolds were implanted subcutaneously in mice.
After 7 days, native tissue had already begun to inﬁltrate the scaf-
folds, with vascularisation seen to develop on histological analysis.
Further to this, HB capacity to induce bone regeneration was
assessed in vivo within a rat spinal fusion model. Pure HA-PLGA
scaffolds and HA-PLGA scaffolds with additional of recombinant
human bone morphogenic protein 2 (rhBMP-2) were implanted. A
demineralised bone matrix (DBM) scaffold was used for compari-
son, with fusion rates of 50e60% usually seen with this control
[301]. After 8 weeks in vivo, bone formation and spinal fusion rates
were similar in the HA-PLGA scaffold compared to the DBM control.
These ﬁndings suggest that without any added growth factors, the
scaffold has intrinsic osteoinductive properties comparable to the
commercially available DBM. HA-PLGA scaffolds with rhBMP-2
were found to have superior new bone formation and spinal
fusion rates compared to both the alone and DBM. HA-PLGA HB
Scaffolds were also implanted into primate calvarial defects, to
evaluate performance in larger cortical bone defects. After 4 weeks
in vivo, implants were excised from the calvarial defects and
examined. Evidence of heavy vascularisation and mineralised tis-
sue advancing into the implants from the cortical bone was seen;
areas not in direct contact with native bone were also seen to
develop mineralised tissue, suggesting up-regulation of osteogenic
gene expression by nativeMSCs without the addition of any growth
factors, indicating HB osteoinductive potential. In summary, 3D
printed HB demonstrated several properties favourable to clinical
use. Compared to DBM, 3D printed HA-PLGA could offer a cheap
and potentially readily available osteoinductive material for clinical
applications, without risk of disease transmission.
Cheng et al. also looked to combine HA and PCL in a 3D printed
Fig. 16. (A) Photograph series showing the compression and recovery of a 1-cm-diameter 3D-printed HB cylinder over a single compression cycle (B) 12  12 cm sheet of HB printed
from 100 ml HB ink, with ease of manipulation into complex folded structures shown (C) SEM image of explanted HB scaffold after 35 days in vivo; blood vessels indicated by yellow
circles, with soft tissue ﬁlling space between HB ﬁbres. Adapted from Jakus et al. [302].
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composite scaffold using stereolithography, which creates 3D
structures through spatially controlling the solidiﬁcation of liquid
photo-polymerizable resin [78,303,304]. Pure PCL scaffolds were
ﬁrst fabricated via a custom designed 3D printer. The scaffolds were
then modiﬁed by immersing them in poly-dopamine (PDA), before
mineralization with HA nanocrystals was achieved on the scaffold
surfaces through a precipitation reaction. Scanning electron mi-
croscopy (SEM) was used to examine HA/PDA/PCL scaffold micro-
structure; mean pore sizes of scaffolds 400 pmwere found, which
has previously been shown to be optimal for bone tissue regener-
ation [305]. Sterilised scaffolds were then seeded with hMSCs and
incubated in appropriate media. Cellular attachment, osteogenesis
and angiogenesis of hMSCs was found to be signiﬁcantly increased
in dopamine-coated scaffolds compared to pure PCL variants.
Furthermore, hMSC proliferation, ALP activity, osteogenesis-related
proteins, and angiogenesis-related protein secretion all increased
as scaffold PDA concentration was increased. These results
demonstrated that dopamine scaffold surface modiﬁcation could
have signiﬁcantly beneﬁcial effects for BTE. Dopamine analogues
have previously been shown to be important in allowingmussels to
attach themselves to rocks [306]. Dopamine has also been applied
to various materials to improve their cell adhesive properties;
metals, oxides, polymers and carbon-based materials have all been
coated with improved cell attachment and differentiation seen
[203,307e309]. Dopamine has also been shown to help inhibit
peri-implant osteolysis caused by inﬂammation [307].
4.4.7. Poly(lactic acid) (PLA) e based composite scaffolds
Poly (lactic acid) is a biodegradable, bioactive thermoplastic
polyester that has been used tomake a number of medical implants
including bone screws, ﬁxation devices and vascular grafts [310].
PLA is formed by the polymerization of lactic acid and can be ob-
tained from renewable sources including starch and sugar. Several
distinct forms of PLA exist due to the chiral nature of lactic acid,
including poly-L-lactide (PLLA) and poly-D-lactide (PDLA) which
are produced from the polymerization of L-lactide and D-lactide
respectively [311].
Yang et al. recently fabricated hierarchical macroporous
biocompatible (HmPB) scaffolds containing a matrix of PLA, PCL
and hydrophobically modiﬁed silica nanoparticles (h-SiO2) [312].
PCL and PLA were ﬁrst dissolved in an organic solvent, with h-SiO2
nanoparticles then added as a particulate emulsiﬁer. After solvent
evaporation, the resulting composite material was 3D printed into
scaffolds with over 98% porosity. The scaffolds had a hierarchical
structure (including macropores, medium pores and small pores)
and supported the adhesion and proliferation of MSCs, suggesting
good biocompatibility.
Holmes et al. created a PLA based scaffold using a fused depo-
sition modelling 3D printer. The scaffolds were designed to have
highly interconnected 3D microvascular-mimicking channels, to
facilitate osteogenic bone regeneration as well as vascular cell
growth. The resulting scaffolds were also chemically conjugated
with nHA to enhance osteo-differentiation of seeded hMSCs. SEM
imaging demonstrated printing of vertical microchannels with both
a 500 and 250 mm radius, within a porous bone matrix. Mechanical
testing also demonstrated that the scaffolds could withstand
normal mechanical loading, exhibiting elastic behaviour. Analysis
of in vitro hMSC adhesion, proliferation and osteogenic differenti-
ation found enhanced results with scaffolds incorporating nHA and
small (250 mm) microchannels, compared to controls without nHA
and with large (500 mm)microchannels. Additional in vitro analysis
with human umbilical vein endothelial cells demonstrated the
scaffolds to be effective in supporting and enhancing vascular cell
growth and activity, with large channel scaffolds promoting the
greatest HUVEC growth. Taking all of the ﬁndings together,
inclusion of both large and small microchannels and nHA may
provide the best overall solution for creating a vascularized, load-
bearing, osteogenic scaffold [313].
In a different approach, Ren et al. recently electrospun a blend of
PLLA and gelatin to create a nanoﬁbrous mesh designed to aid bone
defect repair [314]. The composite mesh was seeded with MSCs,
with osteogenic differentiation occurring after 7 days of in vitro
culture. 3D multi-layered constructs were then built by stacking
four mono-layered meshes together. The constructs were incu-
bated in vitro for 3 days before being implanted into rat cranial
defects. In comparison with a control group, there was signiﬁcant
formation of new calciﬁed bone after 12 weeks. Yao et al. also
created nanoﬁbrous composite PLA scaffolds, by electrospinning a
blend of PCL and PLA [315]. To improve control over structural
properties created by the electrospinning process, an innovative
technique of thermally induced nanoﬁber self-agglomeration
(TISA) was developed by the same group [316]. In brief, this
involved electrospun nanoﬁbrous mats being converted into tiny
nanoﬁbrous pieces, which were then utilised as building materials
for making 3D electrospun scaffolds. Grinding, dispersing,
agglomerating and freeze-drying processes were involved. The
resulting 3D scaffolds had a 96% porosity and possessed inter-
connected and hierarchically structured pores, including macro-
pores with sizes up to 300 mm. On in vitro testing, PCL/PLA-3D blend
scaffolds had higher mechanical properties and in vitro bioactivity
compared to pure PCL-3D scaffolds made by the same process. This
was reﬂected by enhanced hMSC cell viability, osteogenic gene
expression and apatite-like deposition in PLA/PCL scaffold compare
to pure PCL controls. In vivo analysis was then performed, with PCL/
PLA-3D scaffolds implanted into mice cranial bone defects. After 6
weeks, histological analysis suggested that PCL/PLA-3D scaffolds
provided a more favourable/desired microenvironment for mouse
cranial bone formation as compared to the PCL-3D scaffolds, with
signiﬁcantly increased bone formation. Despite this, neither scaf-
fold could bridge the bone defects completely, despite the addition
of BMP growth factor supplement.
4.4.8. Poly(lactic-co-glycolic acid)/PLGA e based composite
scaffolds
PLGA is a synthetic co-polymer of poly-L-lactic acid (PLLA) and
polyglycolic acid (PGA), with US Food and Drug Administration
approval for human applications. Degradation rates of PLGA can be
customised to range from weeks to months, based on the ratio of
PLLA to PGAwithin the copolymer structure [317]. Other beneﬁts of
PLGA over pure PLA and PGA include the range of commonly
available solvents that it can be dissolved in and the ease with
which it can be manipulated into structures of desired sizes and
shapes. Biomolecules such as growth factors can also be easily
encapsulated by PLGA.
However, there are some limitations to the use of PLGA within
BTE. The amorphous structure of PLGA has a low Young's modulus,
resulting in susceptibility to elastic deformation, whilst PLGA is also
poorly osteoconductive [318]. In order to address these limitations,
PLGA has been combined with ceramics and bioactive glasses to
create composite scaffolds [319]. Several groups have combined
nano-HA (nHA) with PLGA, hoping to beneﬁt from the osteogenic
properties and high modulus of nHA [180,320]. Whilst high con-
centrations of nHA in a composite can potentially have adverse
effects on mechanical properties due to non-uniform distribution,
lower concentrations are able to improve tensile and compressive
properties of scaffolds [321,322]. When contained within a com-
posite scaffold, nHA has also been shown to help cells and proteins
attach to scaffold materials [17]. PLGA also potentially balances the
limitations of nHA which include inherent brittleness and slow
degradation [318,323]. Several groups have created composite
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PLGA-nHA scaffolds using the technique of particulate leaching
[324e326]. However, the microarchitecture of scaffolds formed by
this method typically have low porosities and interconnectivity.
Incomplete solvent removal has been also encountered with this
technique, resulting in reduced cell viability. Kim et al. modiﬁed the
technique of particulate leaching by creating a PLGA-nHA scaffold
by gas forming and particulate leaching. This process avoided using
organic solvents, eliminating potential issues associated with
incomplete solvent evaporation, and resulted in improved scaffold
microarchitecture. Higher porosity and improved mechanical
characteristics resulted in higher in vitro cell growth and mineral-
ization of scaffolds, compared to PLGA-nHA scaffolds formed by
solvent casting-particulate leaching [17].
Shaui et al. 3D printed porous PLGA-nHA scaffolds via selective
laser sintering. This method allowed formation of well-controlled
pore architectures and high scaffold surface bioactive nHA con-
tent. The effect of nHA on scaffold mechanical properties was then
investigated; although scaffold compressive strength and modulus
was improved as nHA content increased from 0 to 20%, nHA content
above 20% resulted in worsening, brittle mechanical properties
[129]. To re-create bone extracellular matrix (ECM) structure
several groups have tried to create nano-ﬁbrous PLGA composite
structures via electrospinning; potential beneﬁts of including
nanoﬁbers include high surface area per unit mass, increased
biodegradability and with the addition of ceramic nanoparticles,
improved osteoconductive potential [29,30,128,327]. Jose et al.
electrospun nanocomposite scaffolds, adding nHA to PLGA solution
before spinning. Like Shaui's ﬁndings, nHA content strongly inﬂu-
enced scaffold mechanical properties. Whilst 20% nHA strongly
increased the Young's modulus of the electrospun composite
meshes, higher concentrations again led to worsening mechanical
properties [328]. Yun et al. evaluated the biocompatibility of elec-
trospun PLGA-nHA scaffolds through culturing human primary
adipose tissue-derived stem cells (hADSCs) andMSCs on themwith
promising results. With a nHA content of around 17% (w/w), oste-
ogenic differentiation andmineralization of bothMSCs and hADSCs
occurred. These results were conﬁrmed by increased expression of
osteogenic genes on reverse transcription-polymerase chain reac-
tion (PCR) increased ALP activity and calcium deposition [329].
Haider et al. also evaluated the cell compatibility of PLGA-nHA
composite nanoﬁber scaffolds, by culturing osteoblasts on PLGA
and PLGA-nHA scaffolds to allow direct comparison (Fig. 17). In this
study, the impact of HA morphology was also examined by
comparing spherical and ﬁbre forms of nHA on cell culture results.
PLGA-nHA nanoﬁber scaffolds showed higher cellular adhesion,
proliferation, enhanced osteogenesis and increased Caþ2 ions
release compared to spherical PLGA-nHA and pure PLGA scaffolds.
This study re-iterated the beneﬁcial effects of including nHAwithin
scaffolds on osteoblast culture. The enhanced cell proliferation on
the ﬁbre PLGA-nHA scaffold compared to scaffolds containing
spherical nHA suggested that the morphology of nHA also in-
ﬂuences cell behaviour [330].
Whilst the combination of synthetic polymers such as PCL and
PLGA with HA has led to successful results, natural polymers such
as collagen and chitosan have improved mineralization character-
istics compared to synthetic polymers. The presence of numerous
ionic molecular groups within natural polymers allows for pro-
cesses such as calcium chelation to occur and mineralization rates
are improved by the negative surface charge. The surfaces of syn-
thetic polymers are also largely hydrophobic, which is less
favourable for cell adhesion to occur [331,332]. Attempts have
therefore beenmade tomodify the surface of synthetic polymers to
increase cell afﬁnity. One approach has been to covalently link
arginine-glycine-aspartic acid (RGD) to biomaterials such as PLGA
to facilitate cell adhesion. RGD has previously been established as
the minimal core peptide recognizable by cell adhesion receptors
and is capable of increasing the bioactivity of structures [333]. Shin
et al. fabricated biomimetic hybrid nanoﬁber sheets composed of
RGD peptide-decorated PLGA (RGD-PLGA) nanoﬁbers via an elec-
trospinning technique. Cells including the murine preosteoblastic
cell line (MC3T3-E1 cell) and the human osteosarcoma cell line
(MG-63 cell) were then cultured on the scaffolds. Compared to pure
PLGA nanoﬁber sheets, the initial adhesion and proliferation of cells
were signiﬁcantly enhanced on RGD-PLGA sheets, as found in other
studies [201,202,334].
4.5. Hydrogels
Hydrogels are gels constructed from networks of crosslinked,
hydrophilic polymer chains. Their hydrophilic nature allows them
to absorb copious amounts of water into a three-dimensional
network, which is ideal for supporting cell growth. In fact, hydro-
gels can absorb up to 1000 times their original weight in aqueous
mediumwithout dissolving [335]. At the same time, they are highly
permeable to oxygen, nutrients and other water-soluble com-
pounds, making them attractive materials for tissue engineering
Fig. 17. (A) SEM micrographs of nHA/PLGA composite nanoﬁber scaffolds, with adherent cells after 24 h incubation also displayed (B).
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[182]. Within BTE, they have been shown to facilitate angiogenesis,
osteoconductivity, cell adhesion and matrix integration
[89,336e338]. Hydrogels can be derived from natural polymers
(including collagen, gelatin, alginate, chitosan, hyaluronic acid and
agarose) or synthetic materials. Natural polymers are often derived
from extracellular matrix components including collagen and hy-
aluronic acid, and therefore have low toxicity, high biocompatibility
and cell afﬁnity [339,340]. However, natural polymers can undergo
uncontrolled degradation resulting in compromise of mechanical
properties in printed constructs. To help address this issue, syn-
thetic polymers can be used either alone or with natural polymers
to create a composite hydrogel, allowing better control over stiff-
ness and elastic modulus of hydrogel constructs [341,342]. Syn-
thetic polymers can also be functionalized with biological
molecules, such as RGD, heparin and hyaluronan, to increase
bioactivity and cell adhesion in hydrogel composites [202,343].
Growth factors and drugs have also been encapsulated within
hydrogels to increase scaffold bioactivity [344e346].
Successful bioprinting relies in part on combining a suitable
bioprinting technique with an appropriate bioink. Signiﬁcant focus
within bioprinting has therefore been placed on developing cell-
friendly, novel bioinks which can be 3D printed to fabricate tissue
constructs. Polymeric hydrogels are usually the main component of
bioinks as they have cell-friendly properties whilst being amenable
to 3D printing [338]. Hydrogel-based bioinks are often composite
materials, containing growth media, cells, biomaterials, added
nutrients and growth factors to aid cell proliferation and differen-
tiation [347e349].
4.5.1. Composite bioinks used in bioprinting
Although low-viscosity hydrogels with a high-water content
provide a superior environment for cell function and viability, the
mechanical integrity and support they provide is often insufﬁcient
to allow transfer to in vivo analysis. Attempts have therefore been
made to create composite bioinks capable of integrating the me-
chanical strength of viscous hydrogels with the biocompatibility
provided by lower-viscosity hydrogels.
Nguyen et al. recently designed bioinks to treat cartilage lesions,
containing either nanocellulose with alginate (NFC/A) or
nanocellulose with hyaluronic acid (NFC/HLA). NFC was chosen to
help mimic the collagen bulk in cartilage matrix [350], alginate
used in place of natural proteoglycans, whilst hyaluronic acid was
included as a major component in native cartilage. Human-derived
induced pluripotent stem cells (iPSCs) and irradiated human
chondrocytes were then encapsulated in the bioinks. Utilising a
microvalve 3D bioprinter, a grid construct was printedwith the two
differing bioinks. In the case of NFC/HLA, low proliferation and
phenotypic changes away from pluripotency were seen in the
iPSCs. However, in the case of the NFC/A (60/40, dry weight % ratio)
constructs, hyaline-like cartilaginous tissue with collagen type II
expression was seen after 5 weeks. Additionally, a marked increase
in cell number within the cartilaginous tissue was detected by 2-
photon ﬂuorescence microscopy. The NFC/A bioink therefore
appeared suitable for bioprinting iPSCs to support cartilage pro-
duction in co-culture with chondrocytes. Markestedt et al. also 3D
printed a NFC/A bioink containing human chondrocytes. The shear
thinning properties of the NFC and the fast crosslinking of alginate
allowed microvalve bioprinting to occur with high ﬁdelity and
stability. Taking MRI and CT data, they managed to print anatomi-
cally accurate scale models of human ears and sheep meniscus
(Fig. 18). Chondrocyte viability after printing was approximately
95%, with viability also found of 73% and 86% after 1 and 7 days of
3D culture respectively [351].
Gao et al. used inkjet bioprinting to co-print an acrylated
poly(ethylene glycol) (PEG) hydrogel with acrylated peptides. Hu-
man MSCs were included in the composite hydrogel, which was
exposed to ultraviolet light to initiate simultaneous photo-
polymerization of the hydrogel during printing. The resulting
scaffold demonstrated excellent biocompatibility with a cell
viability of 87.9 ± 5.3% 24 h after printing. Printed constructs con-
taining hMSCs were cultured for 21 days in either osteogenic or
chondrogenic media. Osteogenic and chondrogenic gene expres-
sion was seen to signiﬁcantly increase from day 7e21, with sig-
niﬁcant collagen and extracellular matrix deposition seen.
Mechanical analysis found modulus increases in PEG-Peptide
scaffolds of 100% in osteogenic media and 82% in chondrogenic
media from day 7e21. The compressive modulus of the printed
PEG-Peptide hydrogel exceeded 500 kPa, which is more than 100
Fig. 18. (A) The 3D Discovery (Switzerland) bioprinter with microvalve print-head shown (B) 3D printed knee meniscus using NFC/A ink. Adapted from Markestedt et al. [351].
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times as that reported for some natural hydrogels [352,353].
Overall, the PEG-Peptide hydrogel printed in this study developed
into a homogenous tissue with high cell viability and mechanical
integrity [354].
Kang et al. used a multi-head bioprinter to create an interwoven
scaffold consisting of cell-laden hydrogels, PCL polymer and a
sacriﬁcial Pluronic F127 hydrogel [355]. The composite hydrogel
consisted of optimised concentrations of gelatin, ﬁbrinogen, hyal-
uronic acid (HA) and glycerol mixed into cell culture media. Plur-
onic F127 was printed as a sacriﬁcial outer layer to support the 3D
architecture of the composite hydrogel while crosslinking was
performed, whilst the PCL provided internal scaffold structural
strength. After cross-linking of ﬁbrinogen using thrombin, the
uncross-linked components (gelatin, HA, glycerol and Pluronic
F127) were washed out. This created microchannels in the tissue
constructs, facilitating diffusion of nutrients to printed cells. Tissue
models were printed in anatomically relevant shapes through use
of clinical imaging data, with constructs created to match skull and
mandible defects. The potential of the printing process was
demonstrated through fabrication of mandible and calvarial bone,
cartilage and skeletal muscle. High cell viability was found post-
printing of chondrocytes, amniotic ﬂuid derived stem cells and
myoblasts; cell viability in printed structures was typically 91 ± 2%
after 24 h of culture.
Pluronic F127 has been adapted into several other composite
scaffolds to aid in the creation of temporary structural support or
vascular channels [356e359]. Although F127 has poor cell
compatibility when used alone, it is easy to print and structurally
robust [360e363]. Aqueous F127 solutions undergo thermal gela-
tion at physiological temperatures, but on cooling bellow a critical
micellar temperature (CMT) dissociation of the gel occurs. This al-
lows F127 to be printed as a gel into constructs, with secondary
cooling of the construct then washing F127 away as a fugitive ink
[364,365]. As a result, F127 support structures can be removed
post-printing and printed F127 channels left patent for perfusion
with media. This approach has proved helpful in attempts to create
vascular channels in constructs. Creating a sufﬁcient vascular
structure is a major challenge in bioprinting, as in the absence of a
vascular network cells are dependent on diffusion for delivery of
oxygen and nutrients [361]. Whilst larger vessels have been fabri-
cated, capillaries have yet to be 3D printed, which leaves constructs
dependent on inﬁltration of micro-vessels in vitro to ensure cell
viability. Unfortunately, microvessel inﬁltration often lacks depth of
penetration, limiting the size of viable bone construct that can be
implanted [366,367].
Lewis et all used F127 as a fugitive ink to help create a multi-
material 3D construct with vascular channels (Fig. 19) [368].
A silicone ink was ﬁrst printed and then cured, creating a
Fig. 19. (A) Illustration of tissue manufacturing process (B) Photograph of a printed tissue construct housed within a perfusion chamber. Perfusion inlet and outlet seen at either end
of tissue construct. Adapted from Kolesky et al. [368].
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perfusion chip. Fugitive ink, containing F127 and thrombin, and
cell-laden inks, containing gelatin, ﬁbrinogen, and hMSC cells, were
then printed within the 3D perfusion chip. A composite material
containing gelatin, ﬁbrinogen, cells, thrombin and trans-
glutaminase (TG) was then cast over the printed inks, recreating an
extracellular matrix. After casting, thrombin converted soluble
ﬁbrinogen into insoluble ﬁbrin in the cast matrix. Similarly, TG
diffused from the ECM matrix and slowly cross-linked the inner
gelatin and ﬁbrin. Upon cooling, the fugitive F127 ink liqueﬁed,
leaving behind a pervasive vascular network. This network was
seeded with human umbilical vein endothelial cells (HUVECs) to
induce endothelialisation and perfused via an external pump. The
vascular networks were then perfused with osteogenic media after
6 days of in vitro culture. After 30 days, the printed hMSCs
expressed osteocalcin in the tissue, with osteocalcin expression
found to be highest in areas close to vessels perfused with osteo-
genic media. Collagen deposition was found within printed ﬁla-
ments and around the circumference of the vasculature. Alizarin
staining also revealed a high degree of mineralization within the
tissue. In summary, thick (1 cm) vascularized human tissues were
created and actively perfused with growth factors to differentiate
hMSCs toward an osteogenic lineage in situ over several weeks (>6
weeks).
F127 has also been used in combination with other hydrogels to
increase porosity and produce nanostructures. Muller et al. com-
bined diacrylated F127 (F127-DA) with F127 to print chondrocytes,
with hyaluronic acid methacrylate (HAMA) added to the bioink to
improve mechanical strength [369]. After bioprinting, the F127-DA
was UV crosslinked with the acrylate acting as a photocrosslinkable
group. This allowed the remaining F127 to be washed out on
cooling, subsequently nanostructuring the remaining F127-DA-
HAMA network. To increase gel stiffness and to avoid elution of HA
during the nanostructuring process, HA was functionalized with
methacrylate groups to allow covalent crosslinking between HA
and the F127-DA network. Inclusion of 0.5% HAMA increased the
compressive modulus from 1.4 kPa in a pure F127-Da scaffold to
5.62 kPa in a F127-DA-HAMA composite. Cell viability was main-
tained at an elevated level after 14 days in culture in the F127-DA-
HAMA composite scaffold, with 79.9% of chondrocytes still alive.
Perriman et al. designed a novel pluronicealginate bioink, which
was used in a two-step 3D printing process to engineer bone and
cartilage architectures [370]. Speciﬁcally, 3D structures containing
hMSCs were printed by extruding a shear-thinning, cell-laden
F127-alginate composite gel onto a heated stage, resulting in
instantaneous solidiﬁcation via the solegel transition of the F127.
After printing, CaCl2 crosslinking of alginate and washing steps
were performed to allow the F127 to dissolve out of the printed gel
structure. The F127 constituent acted as a sacriﬁcial template,
creating micron-sized pores and microchannels in the scaffold on
dissolution. Optimization experiments found a 13 wt% F127e6 wt%
alginate composite hydrogel to have the best print characteristics.
MSC-laden 3D printed constructs showed no signiﬁcant loss in cell
viability over 10 days in culture. Encapsulated MSCs were also
successfully differentiated into osteoblasts and chondrocytes
within the F127-Alginate bioink, with a tracheal ring created.
Byambaa et al. also utilised an extrusion-based bioprinting
strategy to fabricate microstructured bone-like tissue constructs,
complete with perfusable vascular lumen [371]. To form a perfus-
able blood vessel in the centre of the construct, a cylinder with 5%
gelatin methacryloyl (GelMA) hydrogel at low methacryloyl sub-
stitution (GelMALOW) was printed containing HUVECs and hMSCs.
The softness of the inner core, prepared with 5% (w/v) GelMALOW,
allowed a fast degradation of the hydrogel, leaving an open lumen
and a perfusable channel of 500 mm after 12 days of in vitro incu-
bation. Three successive layers of cylinders were also initially
printed around the soft core using 10% (w/v) high methacryloyl
substitution gelatin methacryloyl (GelMAHIGH). The GelMAHIGH
was loaded with silicate nanoplatelets to induce osteogenic dif-
ferentiation of hMSCs into osteoblasts, and contained three
different concentrations of covalently conjugated vascular endo-
thelial growth factor (VEGF). The VEGF gradient created different
chemical microenvironments, promoting vascular spreading form
the central vessel into the surrounding bone niche. Synthetic sili-
cate nanoplatelets were included as bioactive agents that dissociate
into products that can trigger osteogenesis (Naþ, Mg2þ, Si(OH)4 and
Liþ) [372]. It has also been reported that silicate nanoplatelets can
induce osteogenic differentiation of encapsulated hMSCs within
GelMA hydrogels [373,374]. In this study, it was found that osteo-
genic differentiation occurred even in the absence of growth fac-
tors, with higher concentrations of silicate nanoplatelets resulting
in increased calcium deposition after 21 days in culture. Overall, the
approach of creating a central lumen and using a composite GelMA-
nanoplatelet hydrogel resulted in the creation of a mechanically
stable construct. Perfusion with growth media facilitated cell sur-
vival, proliferation and osteogenic differentiation over a 21-day
period. Compared to conventional approaches such as the use of
thermoresponsive hydrogels [15,24] or sacriﬁcial templates [26],
this study manged to fabricate a blood vessel through a one-step
bioprinting process. Steps such as exposing constructs to temper-
ature changes to remove sacriﬁcial materials were therefore
bypassed.
Wang et al. ﬁlled a 3D printed bioceramic scaffold with phage
nanoﬁbers to try and overcome the challenge of forming vascu-
larized bone tissue [375]. Firstly, a biomimetic bone scaffold, con-
sisting of a biphasic calcium phosphate (BCP) (with a composition
of hydroxyapatite (HA) and b-tricalcium phosphate (b-TCP) at a
mass ratio of 60/40) was produced via 3D printing. The scaffold
showed a uniform structure with interconnected macro-scale
pores, and contained micro-scale pores on the scaffold columns.
Nanoﬁber phages expressing RGD (Arg-Gly-Asp) were then com-
bined with chitosan and adhered to the construct pores through
electrostatic interactions, with the intention of improving scaffold
osteogenesis and vascularisation in vivo. The constructs were then
implanted in an animal model and native cells invaded the
construct to form vasculature, with MSCs undergoing osteogenesis.
However, the rate of vascularisation was relatively slow with cell
survival within the cell-laden construct impaired as a result.
Costantini et al. printed 3D biomimetic hydrogel scaffolds con-
sisting of differing combinations of gelatin methacrylamide
(GelMA), chondroitin sulfate amino ethyl methacrylate (CS-AEMA)
and hyaluronic acid methacrylate (HAMA) [376]. Using a two
coaxial-needle bioprinting system, they achieved a high cell density
(>107 cells ml1), high cell viability (85 ÷ 90%) and high printing
resolution (z100 mm) post-printing. Bioinks were loaded with
MSCs, with addition of 4% alginate and 0.3 M CaCl2 also performed
to aid crosslinking. All the employed hydrogels exhibited enhanced
chondrogenic differentiation of bone marrow derived-MSCs after 3
weeks of culture in chondrogenicmedium. A composite hydrogel of
alginate, GelMA and CS-AEMA appeared to be the best candidate
for neocartilage formation, as it supported the highest levels of
collagen production.
Daly et al. used a novel approach in trying to create bone tissue,
by bioprinting a structure more representative of a developmental
precursor to adult bone [377]. It was hoped that 3D printing a
rudimentary structure would create a template for subsequent
organogenesis in vivo. An alginate bioink incorporating RGD
adhesion peptides was printed along with a network of PCL ﬁbres.
Addition of PCL ﬁbres resulted in a near 350-fold increase in
construct compressive modulus. The mechanically reinforced
template was printed in the geometry of a primitive vertebral body
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and implanted in vivo. After removal and histological analysis, it
was found to support the development of vascularized bone, with
trabecular-like endochondral bone and a supporting marrow
identiﬁed. It was therefore postulated that developmental engi-
neering approaches could be applied to the biofabrication of other
solid organs, by bioprinting precursors that have the capacity to
mature into their adult counterparts over time in vivo.
Silk-based composite hydrogels have also been used in BTE in
several forms. Kim et al. fabricated a silk ﬁbroin/hydroxyapatite (SF/
HA) composite hydrogel, with hyaluronic acid (HA)-dopamine (DA)
surface modiﬁcation of HA nanoparticles performed to aid distri-
bution of HA content [378]. The composite hydrogel showed
excellent cell proliferation, with in vivo analysis required to fully
examine BTE potential. Park et al. also produced SF composite
hydrogels containing HA nanoparticles (NPs) for bone tissue engi-
neering [379]. In this study gamma-ray (g-ray) irradiation treat-
ment was used to induce rapid chemical crosslinking of a SF
solution containing HA NPs, creating a chemically crosslinked SF
hydrogel. Comparedwith comparedwith the pure SF hydrogels, the
SF/HAP composite hydrogels exhibited improved osteogenic dif-
ferentiation of hMSCs. Ding et al. adapted a hybrid approach,
whereby SF hydrogels were used to deliver rat MSCs to a SF scaffold
[380]. In vivo analysis in a calvarial defect found that encapsulated
cells were still viable and actively participating in new bone for-
mation 8 weeks after implantation. The beneﬁts of cell encapsu-
lation were therefore twofold, as both cell viability and cell
numbers seeded to the scaffold were increased and maintained
in vivo.
Within composite hydrogel scaffolds, several studies have
examined osteogenic differentiation of MSCs, whilst the potential
of human adipose stem cells (hASCs) in vitro and in vivo has been
examined less frequently. Potential beneﬁts of using hASCs over
hMSCS include their abundance in adipose tissue and capacity for
minimally invasive harvesting [318]. Wang et al. printed a hASC
laden 8 wt% alginate and 2 wt% gelatin hydrogel scaffold, with an
interwoven grid structure [381]. Cell viability was 90.41% on day 7
of in vitro culture, with construct structure maintained. Culture in
osteogenic media lead to signiﬁcant increases in osteogenic gene
expression (OSX, RUNX2, and OCN) compared to scaffolds placed in
basal media. The hASC laden composite scaffolds were also
implanted in mice for 8 weeks. Compared to acellular controls,
printed constructs containing cells remained in their original
shape, with blood vessels ingrowth into the apertures of the con-
structs seen. Ectopic bone formation was also seen to occur, with
bone matrix seen to replace part of the degraded scaffold material
on histology, demonstrating bioactivity within the scaffold. This
study therefore showed that 3D bioprinted constructs containing
hASCs can promote mineralised bone matrix formation. Maglione
et al. demonstrated the osteogenic potential of ASCs further by
seeding them onto a chitosan-glycerol phosphate hybrid gel scaf-
fold, which was maintained by in-situ by cross-linking [382]. The
scaffolds were implanted into full-thickness mandible defects, with
ex vivo histological and micro CT analysis performed after 8 weeks.
It was found that ASCs could regenerate bone within the scaffold,
with the scaffold able to entrap and maintain cells in situ.
4.5.2. Injectable hydrogels for bone tissue engineering
Injectable hydrogels have attracted signiﬁcant attention within
bone and cartilage tissue-engineering applications. Potential ben-
eﬁts include the ability to perform minimally invasive injections
and the capacity to mould hydrogels in situ to match irregular
patient defects [383e385].
In one study a chitosan (CS)/b-glycerophosphate (GP)/collagen
(Co) injectable scaffold was fabricated bymixing solutions of CS, GP
and Co together [386]. SEM found the scaffold to have a porous
microstructure, with good biocompatibility and in vitro osteogenic
differentiation of MSCs also demonstrated. In vivo analysis per-
formed in mice found evidence of ectopic bone formation, with
neovascularization and differentiation of MSCs toward osteogenic
lineage supported after 1 month. The C/GP/Co composite gelled at
physiological pH and temperature after 10 min, suggesting this
scaffold may be useful as an injectable in situ gel-forming scaffold
in bone tissue engineering.
To improve mechanical and osteoinductive properties, bio-
ceramics have also been used in injectable hybrid hydrogels. Dessi
et al. included b-tricalcium phosphate (b-TCP) in a b-TCP- chitosan
composite hydrogel which was crosslinked with b-glycer-
ophosphate. The hydrogel exhibited a gel-phase transition at body
temperature, forming a three-dimensional network with strong
rheological properties favouring cellular activity, with enhanced
cell adhesion and proliferation demonstrated compared to cells
cultured in 12 well-plates [387].
Jiao et al. developed an in situ crosslinkable citric acid-based
biodegradable poly (ethylene glycol) maleate citrate (PEGMC)/hy-
droxyapatite (HA) composite [388]. In vitro cell culture with human
osteoblast encapsulation was performed, with enhanced DNA
content, ALP activity and calcium production found in the hydrogel
compared to a control. Ex vivo analysis on a porcine femoral head
then demonstrated that PEGMC/HA could be a potentially prom-
ising injectable biodegradable bone material for the treatment of
femoral head osteonecrosis; in situ crosslinked PEGMC/HA
completely ﬁlled up and reinforced a femoral head defect (Fig. 20)
[389].
Fu et al. created a biomimetic hydrogel composed of triblock
PEG-PCL-PEG co-polymer (PECE), collagen and nano-
hydroxyapatite (nHA) [390]. SEM demonstrated an inter-
connected porous structure in the composite. In vivo performance
was analysed by implantation of the hydrogel in rabbit cranial
defects for up to 20 weeks. Compared to self-healing controls, the
biodegradable PECE/Collagen/nHA hydrogel had better bone
regeneration in addition to good biocompatibility and biodegrad-
ability. Huang et al. fabricated an injectable nano-hydroxyapatite
(nHA)/glycol chitosan (G-CS)/hyaluronic acid (HLA) composite
hydrogel [391]. SEM found the composite hydrogels to exhibit a
porous structure (pore size: 100e350 mm) ideal for BTE. In vitro
culture of osteoblast like cells (MC-3T3-E1) in the hydrogel
conﬁrmed cytocompatibility, with cells found to be attached and
well spread out after 7 days in culture. Yan et al. produced an
injectable and biodegradable composite gel containing hydroxy-
apatite (HA), gelatin microspheres (GMs) and alginate [392]. This
composite hydrogel was calcium-crosslinked in-situ by a previ-
ously developed technique [393]; crosslinking relied on gradual
release of calcium cations from CaCO3, caused by reaction with
glucono-d-lactone (GDL) included in the composite. It was found
that inclusion of HA and GMs successfully improved themechanical
properties of the scaffold, with cell viability in the alginate/HA/GMs
gel scaffolds also increased compared to alginate controls. The
scaffold could elute an embedded anti-biotic, tetracycline hydro-
chloride, over a 21-day period. However, over 40% of the drug was
trapped in the scaffold, perhaps due to the cross-linking processes
and resulting structural changes. Nevertheless, the composite
seemed promising for local treatment of bone pathologies.
A further study utilised GDL, with an injectable calcium silicate
(CS)/sodium alginate (SA) hybrid hydrogel prepared [394]. Once
again in situ cross-linking was induced by calcium ions directly
released from CS through the addition of GDL. SEM found the
scaffolds to have an interconnected porous structure, with pore
sizes ranging between 50 and 200 mm. Rat bonemesenchymal stem
cells (rtBMSCs) cultured in the hydrogels proliferated well, with
hydroxyapatite deposition and ALP activity found, suggesting
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osteogenic potential. The hydrogel was also able to promote
angiogenesis of human umbilical vein endothelial cells. The CS/SA
composite hydrogel seemed well suited to BTE applications, due to
a porous 3D-structure, injectable properties and a capability to
support osteogenesis and angiogenesis.
Zhao et al. created an injectable calcium phosphate-alginate
hydrogel composite with mechanical properties matching cancel-
lous bone [395]. This was achieved through mixing a calcium
phosphate cement (CPC) paste with hydrogel microbeads encap-
sulating human umbilical cord mesenchymal stem cells
(hUCMSCs). The composite seemed cell-friendly, with viability after
injection matching that in pure alginate and prior to injection.
Mechanical properties including elastic modulus, work of fracture
and ﬂexural strength of the construct matched the reported values
of cancellous bone, and were much higher than many previous
injectable polymeric and hydrogel carriers. hUCMSCs in the
injectable constructs also osteodifferentiated, with high ALP,
osteocalcin and collagen type I expression found after 7 days in
culture. In fact, mineralization by hUCMSCs after 14 days was 100-
fold that found after 1 day in vitro. In conclusion, a fully-injectable,
mechanically-strong, stem cell-CPC scaffold construct was
developed.
A further study produced an injectable thermosensitive hydro-
gel containing zinc-doped chitosan/nanohydroxyapatite/beta-
glycerophosphate (Zn-CS/nHA/b-GP) for bone tissue repair in vitro
and in vivo [396]. The hydrogels exhibited sol-gel transition at
37 C, ideal for use in clinical interventions. The presence of nHA in
the Zn-CS/nHA/b-GP hydrogel enhanced swelling, protein adsorp-
tion, and exogenous biomineralization. Osteoblast differentiation
under osteogenic conditions in vitro and bone formation in vivo in a
rat bone defect was also accelerated by the presence of nHA, with
increased deposition of apatite and collagen found. This study
therefore further underlined the importance of nHA in composite
hydrogels for BTE.
Further studies have taken advantage of nanocomposite
hydrogels [397,398], with one in particular developing an injectable
hydrogel composed of chitin, poly (butylene succinate) (PBSu),
ﬁbrin nanoparticles (FNPs) and magnesium-doped bioglass (MBG)
[399]. Composite gels with 2% FNPs and 2% MBG were found to be
non-toxic to cells, leading to in vitro analysis. Delivery of the
composite gel to aortic tissue lead to enhanced sprouting of blood
vessels, with osteoblastic differentiation, expression of ALP and
osteocalcin conﬁrming the osteoinductive property of MBG. The
osteogenic and vasculogenic potential of this composite hydrogel
would therefore seem promising for bone regeneration. Miri et al.
also incorporated bioactive glass into a composite scaffold, creating
an injectable dense collagen (IDC)- Bioglass) (IDC-BG) hybrid gel
scaffold [400]. In vitromineralization of IDC-BG gels was conﬁrmed
as early as day 1 in simulated body ﬂuid, which progressively
increased up to day 14. Implantation in adult rats found minerali-
zation, neovascularization and cell inﬁltration into the scaffolds
was enhanced by the addition of BG. After 21 days in vivo, there was
evidence of remodelling of granulation tissue into woven bone-like
tissue in IDC-BG scaffolds in ectopic sites. The IDC-BG composite
therefore appeared to be a malleable and osteoinductive bone graft
that mineralizes under physiological conditions.
4.5.3. Injectable hydrogels for cartilage regeneration
Several natural and synthetic bioactive materials have been
used to create injectable hydrogel scaffolds for cartilage regenera-
tion. Examples that have been used successfully include hyaluronic
acid, chitosan, collagen, elastin, alginate, glycopeptides [401e407]
and synthetic polymers [408,409].
Hyaluronic acid has a known ability to aid chondrocyte differ-
entiation, ECM deposition and proliferation [410e413]. These ef-
fects are at least partly achieved by the presence of chondrocyte
surface receptors including CD44, which directly bind to hyaluronic
acid and internalize it via endocytosis [414e416]. Park et al. created
an injectable hyaluronic acid (HLA) and methacrylated glycol chi-
tosan (MeGC) hydrogel by photo-crosslinking with a riboﬂavin
photoinitiator under visible light [417]. Increasing the crosslinking
time from 40 to 600 s signiﬁcantly enhanced the compressive
modulus of the hydrogels from 11 to 17 kPa; however, encapsulated
cell viability also reduced to 60e65% (from 90% after 120 s) with
prolonged crosslinking. Compared to MeGC controls, incorporation
of HLA in MeGC hydrogels increased the proliferation and deposi-
tion of cartilaginous extracellular matrix by encapsulated chon-
drocytes, with high cell viability of ~80e87% over a 21-day culture
period seen. Given these results, this hydrogel would appear to
have exciting potential for cartilage regeneration.
Guo et al. prepared hydrogels of collagen/chondroitin sulfate/
HLA for cartilage regeneration [418]. This was achieved via two
simultaneous processes of collagen self-assembly and crosslinking
polymerization of chondroitin sulfate-methacrylate (CSMA) and
Fig. 20. (A) PEGMC/HA composite being injected into collapsed femoral head; and (B)) Cross-sectional view of femoral head with injected composite visible. Crosslinking was
achieved within 5 min of injection. Adapted from Jiao et al. [388].
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hyaluronic acid-methacrylate. An interpenetrating polymeric
network (IPN) structure was achieved through this process, partly
replicating the structure of native cartilage extracellular matrix.
The composite hydrogel was found in vitro to upregulate cartilage-
speciﬁc gene expression and promote chondrocyte secretion of
glycosaminoglycans and type II collagen.
Yu et al. created an injectable hyaluronic acid/PEG (HLA/PEG)
hydrogel through integrating two cross-linking processes,
including ﬁrstly enzymatic crosslinking and subsequent Diel-
seAlder click chemistry [419]. Enzymatic crosslinking resulted in
fast gelation of the HLA/PEG hydrogel in 5 min, leading to the for-
mation of an injectable material. ATDC-5 chondrocytes encapsu-
lated in the hydrogel showed high metabolic viability and
proliferation. From a mechanical point of view, the hydrogel could
recover from repeated compression to restore initial shape. Taking
the cell-friendly and anti-fatigue properties together, this com-
posite could have potential for cartilage regeneration with further
in vitro analysis required.
Chen et al. recently developed an injectable HLA/RGD-
functionalized pectin hydrogel for cartilage tissue engineering
[420]. Pectins are natural polysaccharides found in most primary
cell walls and have excellent hydrophilic properties. They have
been used within bone and cartilage regeneration to act an ECM
alternative, helping to immobilize cells [421,422]. In vitro analysis
found signiﬁcant production of collagen, glycosaminoglycans and
aggrecans with high cell viability after encapsulation in the HLA/
RGD hydrogel. After 8 weeks of implantation in mice, the scaffold
was well tolerated, with minimal inﬂammation and integration
with surrounding subcutaneous tissues seen.
Choi et al. created an injectable type-II collagen (Col II) and
chondroitin sulfate (CS) composite hydrogel for cartilage regener-
ation [423]. The composite gel was crosslinked by exposure to
visible blue light (VBL) in the presence of riboﬂavin. Whilst un-
modiﬁed chitosan hydrogel supported proliferation and deposition
of cartilaginous ECM by encapsulated chondrocytes and mesen-
chymal stem cells, incorporation of Col II or CS into chitosan
hydrogels further increased chondrogenesis. Col II was found have
the biggest impact on chondrogenesis and cell proliferation in vitro,
thought to be related to integrin a10 binding to Col II, increasing
cell-matrix adhesion.
Alginate has also been utilised in composite hydrogels for
cartilage regeneration with some success. One study combined
oxidized alginate and hyaluronic acid in a composite hydrogel (Al/
HLA), with in vivo analysis in mice performed [424]. Six weeks after
chondrocyte-loaded AL/HLA gels were injected subcutaneously
into mice, effective cartilage regeneration was observed on histo-
logical analysis. Moreover, substantial secretion of sulphated gly-
cosaminoglycans and expression of chondrogenic marker genes
was found, with signiﬁcantly better results demonstrated
compared to control scaffolds. A similar scaffold composed of
alginate and low molecular weight hyaluronic acid was produced
by Park et al., with calcium crosslinking also performed [425]. Once
again, hyaluronic acid bound to alginate triggered chondrocyte
differentiation to a much higher degree than found in pure alginate
scaffolds. Scaffold stiffness was also found to be critical in triggering
chondrocyte differentiation, with low scaffold stiffness leading to
diminished chondrocyte differentiation. It was therefore concluded
that hydrogels require deﬁned polymer compositions and me-
chanical properties, to best regulate chondrocyte differentiation
and phenotype.
Lee et al. created an injectable collagen/hyaluronic acid/ﬁbrin-
ogen composite gel, which they inserted into rabbit osteochondral
knee defects along with MSCs. Histological analysis of the scaffolds
found glycosaminoglycans and type II collagen production within
the extracellular matrix. After twenty-four weeks, the defects had
been repaired with hyaline-like cartilage, demonstrating the strong
therapeutic potential of this composite hydrogel [426].
Composite scaffolds for cartilage regeneration have also been
produced from degradable synthetic polymers such as poly-
ethylene glycol (PEG) and poly(L-glutamic acid) [408,427e430].
Hyaluronic acid/PEG-based injectable hydrogels were prepared via
a dual cross-linking by Dubbini et al., with thermal gelation at
occurring at 37 C [431]. Through altering polymer content, degree
of vinyl sulfonation and degree of thiolation it was possible to alter
the gelation kinetics, mechanical properties, swelling and degra-
dation times of the scaffolds. The composite hydrogels also sup-
ported MSC and ﬁbroblast growth in vitro over 21 days.
5. Barriers to clinical translation
Despite extensive research and several thousand papers pub-
lished on bone and cartilage tissue regeneration, autologous bone
grafts continue to represent the gold standard treatment for
critical-sized bone defects. Several factors have contributed to the
slow translation of research from the bench side to the bedside,
including technical, collaborative and regulatory issues
[192,432,433].
5.1. Scientiﬁc and technological challenges
Addressing all the technical demands faced by a BTE scaffold is a
complex task, with success in one design aspect often coming at the
expense of performance in another area. Current technical chal-
lenges include:
 Choice of scaffold cell content [434,435]. Whilst inclusion of
cells in bone and cartilage regenerative therapies is undoubtedly
beneﬁcial, the most effective cell type remains unclear.
Mesenchymal stem cells have frequently been used clinically
and experimentally with varying degrees of success depending
on method of delivery. However, there is potential risk of
morbidity associated with their collection from bone marrow,
and their regenerative capacity decreases with patient age
[436,437]. Embryonic (ESCs) and induced-pluripotent stem cells
(iPSCs) have also been investigated. These cells are not ordi-
narily involved in adult tissue repair and can require signiﬁcant
laboratory manipulation. Further limitations include teratoma
risk and ethical considerations [438,439].
 Introducing sufﬁcient scaffold vascularisation [13,302,368,371].
In the absence of a vascular network, cells are dependent on
diffusion for survival [361]. Whilst larger vessels have been
fabricated, capillaries have yet to be 3D printed, which leaves
constructs dependent on inﬁltration of micro-vessels in vitro to
ensure cell viability. Unfortunately, inﬁltration of microvessels
often lacks depth of penetration, limiting the size of viable bone
construct that can be implanted [366,367].
 Achieving precise control over scaffold degradation
[132,251,440]. If a scaffold degrades too quickly, mechanical
failure can occur. Similarly, if a scaffold does not degrade sufﬁ-
ciently quickly, an inﬂammatory response could be triggered,
impairing tissue regeneration. Balancing degradation levels
with new host tissue formation has so far proved challenging
[26].
 Improving structural biomimetic properties
[277,334,374,387,441,442]. Although gross 3D scaffold geometry
for individual patient defects can be identiﬁed by magnetic
resonance or computed tomography imaging, successful repli-
cation of anatomy at the microscale remains challenging with
current fabrication methods. The current standard STL ﬁle
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format used to control 3D bioprinters faces limitations in ability
to describe internal pore architecture [443].
 Improving scaffold mechanical properties [313,355,442].
Tailoring scaffold mechanical performance to individual defects
remains difﬁcult, as anatomical loading conditions for individual
defects are difﬁcult to quantify. Achieving satisfactory me-
chanical performance requires a range of properties to be
addressed during scaffold fabrication, including compressive,
tensile, elastic and fatigue resistance, and successful replication
of these properties can help stimulate osteogenesis and perhaps
facilitate degrees of load bearing to occur [55,80,169,440,442].
 Scaling up biofabrication and scaffold production to treat large
scale defects and a potentially high number of patients
[432,444]. High resolution bioprinting methods including laser-
assisted and inkjet techniques currently provide low volume,
smaller-scale manufacturing solutions. However, extrusion
bioprinting may offer a larger scale method for producing
structures suitable for clinical use [445].
Selection of the optimum scaffold fabrication method therefore
remains challenging, due to the extensive variety of manufacturing
methods, biomaterials, cell types and growth factors that have been
investigated, with conﬂicting data available in some cases. Pro-
ducing a scaffold that can address all technical requirements is also
extremely challenging. For example, as scaffold porosity is
increased to improve cell migration and diffusion of nutrients,
scaffold mechanical strength is often reduced [445].
5.2. Translational challenges
In addition to technological and scientiﬁc challenges, signiﬁcant
research and development barriers to translation also exist.
 Obtaining external funding and grants for product development
represents a signiﬁcant hurdle. The cost of performing preclin-
ical and human clinical trials is substantial, and can extend to
hundreds of millions of dollars [446,447]. Despite considerable
time and ﬁnancial investment, there are also no guarantees of
product approval. A trail of bone graft material containing BMP
for spinal fusion was ultimately rejected, despite 5 year follow
up of nearly 500 patients [448]. Following signiﬁcant cost and
time investment in clinical trials, approval is only given for a
speciﬁc scaffold composition to be used for a speciﬁc clinical
indication. Therefore, if an individual scaffold is to be licenced
for use in both tibial non-union and lumbar spine fusion, it may
have to undergo separate clinical trials despite potentially being
unchanged as a product. The inclusion of a drug in a scaffold will
also necessitate further human clinical trials, with further reg-
ulatory and ﬁnancial challenges associated. As a result, some
20e50% of drug candidates fail to translate from preclinical
trials to human clinical trials, potentially costing hundreds of
millions of dollars [449,450].
 The time and cost of meeting complex regulation has also
increased substantially in recent decades. The resources of large
multinational ﬁrms are often required to deliver new products
to large patient populations as a result [451].
 There is therefore a potential lack of “ﬁrst mover advantage” in
that research pioneers can be faced simultaneously with regu-
latory and funding challenges, at the same time as attempting to
resolve scientiﬁc and technical problems that emerge [451].
There are further constraints faced by researchers undertaking
collaborative, translational research. Through close collaboration
with orthopaedic clinicians, as the end users of BTE constructs, it is
hoped that 3D bioprinting and biofabrication strategies can
undergo clinical translation in a streamlined manner from the
“bench to the bedside”. However, it can be difﬁcult for surgeons to
spend quality time in the laboratory as an ageing population is
leading to rising clinical demand and health service ﬁnancial
pressures. In general, as research translational potential increases,
costs increase and progress slows. This also has challenges for ac-
ademics, who may have to produce a steady stream of data and
publications as evidence of productivity to maintain job security
and career progression [192,449].
5.3. Ethical issues
Whilst biofabrication approaches including 3D bioprinting offer
great hope for the future, many of the technologies in use are
expensive and ethical issues may be associated with their future
implementation.
 Despite the promise and hype of tissue and organs being printed
on-demand for speciﬁc indications, the cost of implementing
the technology may lead to only those who can afford to pay for
their ‘own’ tissue or organs beneﬁtting. As a result, bio-
fabrication therapies may initially face limited translation into
wider medical practice, with usage determined by individual
patient access to funding [452,453].
 The risks associated with placing bioprinted cells into the hu-
man body are currently difﬁcult to quantify due to a lack of long-
term in vivo studies. Potential for teratoma formation and
dislodgement and migration of cells from implanted constructs
could exist depending on cell types used. Further questions
remain to be addressed, such as long term biomaterial degra-
dation, tissue integration and biocompatibility [454].
 Stratifying the clinical risk of using a technology developed from
personalized cell sources and biomaterials to the entire popu-
lation could be difﬁcult to achieve.
 Not all patients will ﬁnd it acceptable for their cells to be mixed
with biomaterials that may be animal derived.
 As the technology develops, the boundaries of what can be
achievedmay advance such that new types of tissues and organs
can be produced with superior functionality to the human body.
Robust regulation and governance will need to develop to
ensure responsible, safe and ethical use of the technology [452].
5.4. Future perspectives
It has been suggested by Mironov et al. that the remaining
challenges faced in creating complex tissue and organ constructs
include “achieving the desired level of cell density, effective vas-
cularisation and accelerated tissue maturation” [455]. A number of
developments would be beneﬁcial in helping work towards these
challenges:
 A scalable method of directing osteogenic differentiation would
be advantageous, potentially reducing reliance on differenti-
ating media and increasing costdeffectiveness. As an example,
Dalby's team in Glasgow used nanoscale vibrations delivered by
a nanovibrational bioreactor to differentiate MSCs seeded in
collagen gels into mineralised tissue in 3D. This technology
would appear to be readily scalable, compatible with 3D scaf-
folds, easy to maintain compared to rotary/perfusion chamber
bioreactors and could be used “off the shelf” [456].
 It is already well demonstrated that MSC spheroids exhibit
enhanced in vitro and in vivo osteoregenerative potential
compared to MSCs cultured in monolayer. Increasing incorpo-
ration of organoids and spheroids into bioprinting could help
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accelerate the growth of printed constructs towards clinically
relevant, functional tissue [86,367,455,457,458].
 Development of smart hydrogels, with tailored and tuneable
properties such as mechanical stiffness, degradation rates and
increased bioactivity could help expedite maturation of 3D
constructs [459].
 Increasingly biomimetic construct microarchitectures may be
produced by incorporating approaches such as sophisticated
clinical imaging and mathematical modelling into
manufacturing of scaffolds [460].
 Inclusion of increasingly novel biological cues into bioprinted
constructs could also help expedite their maturation towards
complex, biologically functional tissue. In addition to growth
factors, microRNAs could have a role to play in this area. These
small encoding RNAs have been shown to be capable of differ-
entiating MSCs into osteoblasts and chondrocytes by regulating
post-transcription gene expression. Although understanding is
developing, spatially 3D printing miRNAs into constructs could
be used to help drive vascularisation and formation of osteo-
chondral tissue in 3D constructs [461,462].
 Surface modiﬁcation also has a signiﬁcant role to play in the
future development of biomaterials and tissue engineering
scaffolds for bone and cartilage tissue repair and regeneration.
We have already seen beneﬁcial effects on osteogenic differen-
tiation caused by immobilisation of biological factors such as
BMP, collagen, apatite and polydopamine on scaffold surfaces
[121,282,303,306,463]. Engineering micro- and nanometre sur-
face topography into scaffolds is also critical for promoting
osteoinduction and directing cellular adhesion, spreading, and
proliferation. Nano-topography signiﬁcantly inﬂuences osteo-
conductivity and osseointegration of BTE constructs. It has also
been found that osteoblasts demonstrate increased cell adhe-
sion and proliferation, ALP activity, and enhanced expression of
osteoblast differentiation markers including RunX2, osteocalcin,
and bone sialoprotein (BSP) on nano-featured biomaterials
[464e466].
 Biomaterial surface topography and micro/nano-scale architec-
ture has also been found to play a signiﬁcant role in modulating
and activating the immune system. Cao et al. demonstrated
increased tissue regeneration and decreased inﬂammatory re-
action in scaffolds with aligned ﬁbre topography compared to
scaffolds with randomly aligned ﬁbres [467]. Biomaterial sur-
face treatments may also be used to reduce local degradation or
to deliver bioactive molecules [468].
 Scaffold-induced cell homing is a further approach that may
beneﬁt bone and cartilage regeneration in future. Various
methods have been investigated to achieve enhanced cell
homing to defect sites. Through controlled release of chemo-
kines responsible for MSC homing, it is possible that bioprinted
scaffolds placed into defects will be able to better recruit local
cells for tissue regeneration. Although the mechanisms of cell
mobilization have yet to be fully understood, several key mol-
ecules have been identiﬁed as important factors in attracting
MSCs, including speciﬁc chemokine receptors (e.g., CCR1,
CXCR4, CXCR5 and CXCR6) [468,469].
 Ultimately, increasing biofabrication scalability will require
development of an integrated, standardized biofabrication line.
Mironov et al. suggest that “It is not sufﬁcient to develop just
one robotic deviceda bioprinter … [it] will require the devel-
opment of series of integrated automated robotic devices, or an
organ biofabrication line” [455]. It will therefore be necessary to
develop current biofabrication platforms from novel and
bespoke systems towards high throughput, standardized sys-
tems suitable for clinical practice. This remains a signiﬁcant
challenge that will have to be surmounted to allow bio-
fabrication to be adapted into larger scale clinical practice.
 Finally, to advance and scale-up bioprinting-based technologies
and models, long-term, cross-discipline collaboration is neces-
sary to enable sharing of expertise and increase research
efﬁciency.
6. Conclusions
Critical-sized bone defects have increasing prevalence and
remain a great challenge for both tissue engineers and orthopaedic
surgeons to repair, despite substantial and novel research into their
treatment. Current challenges include tailoring scaffold degrada-
tion, improving structural biomimicry, incorporating sufﬁcient
vascularisation and scaling up of scaffold production to treat large
scale defects in a potentially high number of patients.
As scaffold manufacture has increasingly looked to include
composite materials with increased bioactivity, we have seen
desirable mechanical and cell-friendly properties combined into
single tissue-engineered constructs. Several examples of successful
bone and cartilage constructs with clinical translation have been
developed as a result, with ceramic and polymer composites
perhaps having the greatest success. To maximise osteogenesis and
chondrogenesis in future, it will be necessary to achieve yet closer
replication of natural mechanical and biochemical stimuli that cells
are exposed to, in addition to increasing construct vascularisation.
This may be achieved in part through advances in biomaterials,
scaffold manufacturing techniques and computational modelling.
More effective methods are also required to streamline the process
of cell isolation, culturing and seeding into constructs. This is a
labour and time intensive process at present, although advances in
bioreactor technology may increase efﬁciency. However, the
quickest route to success may be to utilise the natural bioreactor
provided by native bone tissue, which has extraordinary regener-
ative capacity. In this way, in vivo bone and cartilage tissue regen-
eration may be maximised when combined with increasingly
bioactive, anatomically sophisticated scaffolds capable of recruiting
host cells.
3D biofabrication and bioprinting technologies offer increas-
ingly precise control over construct microarchitecture and spatial
content. When combined with the developing array of available
bioactive materials, growth factors, functionalization techniques
and biomimetic scaffold designs, the potential for creating complex
BTE scaffolds tailored to patient-speciﬁc applications in the future
is vast. This also offers hope for the treatment of a variety of chal-
lenging conditions, including osteonecorosis, osteoporosis and
critical bone defects. As scalability and manufacturing methods
continue to develop, it is hoped that treatment tailored to the in-
dividual patient can be produced in an increasingly cost effective,
efﬁcient and reproducible manner in the future.
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